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Abstract  
 
The human DEAD-box RNA helicase DDX3X has previously been shown to be 
involved in innate immune signalling in pathways mediated by IKKε and TBK1. In 
this work we show that DDX3X is also involved in pathways independent of these 
kinases, and functions by interacting with two related kinases IKKα and NIK. 
DDX3X enhances the activation of IKKα and subsequently, augments the activation 
of pathways that IKKα regulates. We show that DDX3 is involved in two important 
signalling pathways that are mediated by IKKα – the alternative NF-κB pathway and 
the TLR7 signalling pathway to type I IFN induction. We propose that DDX3X acts 
as a scaffolding protein that brings together IKKα and its substrates.  
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1 Introduction  
1.1 The  Human  Immune  System  
The human immune system is a complex multifaceted system that is able to adapt 
and adjust in response to almost any threat it may encounter, including bacterial, 
fungal, viral and parasitic infections. It must be able to distinguish between ‘self’ and 
‘non-self’. It must recognise when a pathogen is present, mount an effective, but 
regulated, response and finally bring that response to an end, with as little damage to 
self as possible. The immune system is generally considered to consist of two main 
parts: the innate and the adaptive system.  
The innate response is non-specific in nature and is typically the first line of defence 
against pathogens. The skin and mucosal layers are the first physical barrier against 
incursion. They both function by attempting to prevent initial entry; the skin, by 
constantly shedding epithelial cells taking any bacteria present with them, and the 
mucosal layers, which are chemical barriers that protect epithelial layers, by stopping 
microorganisms from adhering. 
The next level of defence, if the initial physical barriers have been broken through, is 
the complement system. Complement is a key part of both the innate and the 
adaptive immune response. It results in the destruction of pathogen, either directly by 
lysis of susceptible microbes, or indirectly by opsonisation, or enhancement of the 
antibody mediated response. 
If the pathogen is not destroyed immediately by complement, the cells of the innate 
immune system come into play. There are a number of innate immune cells, 
including macrophages, dendritic cells, Natural Killer (NK) cells, neutrophils, 
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eosinophils, basophils and mast cells. Macrophages and dendritic cells (DCs) 
possess pattern recognition receptors (PRRs) which recognise conserved structures 
that are found on a wide range of pathogens, so-called “pathogen associated 
molecular patterns” (PAMPS). Each PRR specifically recognises particular PAMPs; 
this recognition induces signalling pathways and forms the basis for one of the most 
important parts of the innate immune system. These PRR-induced signalling 
pathways promote inflammation by inducing the production of inflammatory 
mediators which can establish a response to clear the infection. This is primarily 
done by attracting other leukocytes to the site of infection. This is achieved, for 
example, by dilating blood vessels to increase blood flow to the area and allowing 
extravasation of leukocytes from blood vessels into the surrounding tissue, or by 
releasing chemoattractants, which guide the leukocytes in, and by releasing 
cytokines that activate them. Neutrophils are the most common leukocyte and are 
usually the first cells to appear at the site of infection. They possess granules which 
contain toxic substances that can damage pathogens. They are known (along with 
macrophages and dendritic cells) as phagocytic cells, which can engulf the pathogen 
and degrade it. Eosinophils and basophils also contain granules, and are usually 
associated with parasitic infections and allergic reactions. As parasites are usually 
too large to be taken up by cells, these cells instead release their granules onto the 
parasite. Another important type of innate cell is the natural killer (NK) cell. The NK 
cell releases its granules onto the surface of the target cell; inducing apoptosis and 
thereby killing both the cell and any viruses inside.  
While the innate immune system is an immediate response, it does not act alone: the 
adaptive response takes over when it has had the time to build up cell numbers 
specific to the antigen. Macrophages and DCs are professional antigen-presenting 
23 
 
cells (APCs) which serve as a bridge between the innate and adaptive systems. They 
can phagocytose microbes, break them down and present the peptides on Major 
Histocompatibility Complex (MHC) molecules to cells of the adaptive system for 
specific recognition, thereby amplifying the immune response. In addition, PRR 
stimulation upregulates co-stimulatory molecules that are needed for activation of T-
cells and induces cytokines that shape T-cell differentiation. 
The adaptive part of the immune system is important because it can give a more 
specific and stronger response to a particular antigen. A key aspect of the adaptive 
response is immunological memory, whereby the immune system ‘remembers’ a 
particular antigen and mounts a stronger and quicker response if re-infected.  The 
major types of cells involved are B cells and T cells. If a CD8+ T-cell recognises an 
MHC-I/Peptide complex it will differentiate into a cytotoxic T-cell that can induce 
apoptosis and kill infected cells directly. Apoptosis of infected cells limits the time 
viruses have to replicate, reduces the number of virions produced and can interrupt 
cycles of latency and reactivation in persistent viruses. Recognition of an MHC-
II/Peptide complex by CD4+ T-cells results in their differentiation into T helper 
cells, which can release cytokines and activate macrophages and B cells. B cells 
produce antibodies that are specific for a particular antigen. Once a B cell is 
presented with its specific antigen it differentiates into plasma cell, which will 
produce a great quantity of antibodies for the specific antigen. When activated, both 
T and B cells will also differentiate into memory cells that can be activated rapidly if 
re-infection occurs.   
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1.2 Immune  response  to  viruses  
Even though the immune system can be challenged by a wide range of pathogens, 
one that is of particular interest to us is viral infection. Viruses have co-evolved with 
their natural hosts for millions of years (Koonin et al. 2006) and, as such, have 
evolved many strategies to subvert host immune responses to allow their replication 
and proliferation (Holmes 2007). There are particular aspects of the immune system 
that are important in the response to viruses. Although the adaptive branch is 
significant, of particular interest to us is the initial innate response that is mediated 
primarily by PRRs. There are a number of families of PRRs, the most relevant to 
viral infections are the Toll like receptors (TLRs), RIG like Helicase receptors 
(RLHs) and cytoplasmic DNA receptors (Thompson et al. 2011). A common 
outcome from all these anti-viral PRRs is the activation of IKK family members 
which subsequently can activate transcription factors such as NF-κB family 
members or Interferon Regulatory Factors (IRFs) (Colonna 2007), that will induce 
production of anti-viral mediators.  
The IKK family consists of 4 members, the canonical IKKs, IKKα and IKKβ, and 
the IKK-related kinases IKKε and TBK1. The IKK-related kinases are best known 
for their involvement in type 1 interferon induction by phosphorylating IRF3 and 
IRF7 (Hemmi et al. 2004; Sharma et al. 2003; Fitzgerald, McWhirter, et al. 2003), 
and the canonical kinases are best known for their role in the classical NF-κB 
pathway where they induce degradation of the inhibitory IκB subunit.  
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1.2.1 Anti-­‐Viral  Pattern  Recognition  Receptors  
1.2.1.1 Toll-­‐Like  Receptors  
There are 10 known TLR proteins found in humans, named TLR 1-10, these 
receptors each recognise a particular PAMP found on invading pathogens. TLRs are 
named after the Drosophila melanogaster protein Toll, which was first discovered in 
1985 as being a key player in the establishment of dorsal-ventral polarity in embryo 
development (Anderson et al. 1985). Involvement of the Toll protein in host-defence 
only came to light in 1996 when it was shown to be involved in expression of the 
antifungal peptide, drosomycin (Lemaitre et al. 1996). At this time it was noted that 
there were similarities between Toll signalling and IL-1 signalling in humans and it 
wasn’t long until a homologue for the Toll protein was found in humans (Medzhitov 
et al. 1997). Since then there has been an immense amount of work carried out 
identifying the other TLRs and characterising the pathways that they induce. The 10 
TLRs and some of their ligands are listed in  
Table 1. 
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Toll-Like 
receptor 
Ligand Cellular location PAMP 
Possession 
TLR1/2 dimer Triacyl lipopeptide Outer membrane Bacteria/Fungi 
TLR2/6 dimer Diacyl lipopeptide Outer membrane Bacteria/Fungi 
TLR3 Double stranded 
RNA 
Endosomes Viruses 
TLR4 LPS Outer membrane Bacteria 
TLR5 Flagellin Outer membrane Bacteria 
TLR7 Single stranded 
RNA 
Endosomes Viruses 
TLR8 Single stranded 
RNA 
Endosomes Viruses 
TLR9 CpG DNA Endosomes Bacteria/Viruses 
TLR10 Unknown   
 
Table 1: List of the ten known human Toll-Like Receptors.  
The cellular location of each TLR is listed along with their cognate ligand and the 
pathogens that possess these ligands (Chang 2010; Kawai & Akira 2010). 
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1.2.1.1.1 TLR  Adaptors    
The TLRs belong to the IL-1R/TLR superfamily, all of which possess cytoplasmic 
Toll/IL-1R receptor (TIR) domains (Watters et al.). These domains are essential for 
mediating the downstream signals induced by TLR receptor engagement. They 
mediate a homotypic interaction between the receptors and TIR domain containing 
adaptor proteins. Differential recruitment of these adaptors confers the specificity of 
signalling pathways that are induced following TLR–ligand binding, by providing a 
linker between TLR and downstream kinases, forming a signalling complex (Ve et 
al. 2012). Myeloid Differentiation gene 88 (MyD88) was the first adaptor to be 
found and is related to the IL-1R and the drosophila Toll gene (Hultmark 1994). 
MyD88 possesses a C-terminal TIR domain, which mediates its interaction with the 
TLRs, and an N-terminal death domain that interacts with a family of kinases known 
as the IL-1R associated kinases (IRAKs) (Wesche et al. 1997; Muzio et al. 1997). 
MyD88 mediates signalling from all TLRs except TLR3 (Alexopoulou et al. 2001), 
which can induce downstream signalling events, including NF-κB activation, 
independent of MyD88. TLR3 instead uses the adaptor TIR-domain-containing 
adaptor-inducing interferon-β (TRIF) (Yamamoto et al. 2002). TLR4 also induces a 
MyD88-independent pathway, which uses TRIF along with another adaptor known 
as TRIF-related adaptor molecule (TRAM) (Fitzgerald, Rowe, et al. 2003). There are 
additional adaptor proteins, including Mal (also known as TIRAP, TIR domain 
containing adaptor protein), which associates with TLR4 and TLR2, and serves as a 
bridge to recruit MyD88 (O’Neill & Bowie 2007), and sterile-α and armadillo motif 
containing protein (SARM) (O’Neill et al. 2003), which is a negative regulator of 
TRIF dependent signalling (Fitzgerald et al. 2001; Horng et al. 2001; Bernard & 
O’Neill 2013; Carty et al. 2006).  
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1.2.1.1.2   TLR  signalling  to  NF-­‐κB  activation  
The recruitment of MyD88 via its TIR domain frees its death domain which allows it 
to act as a scaffold protein for IRAK proteins, including IRAK 1,4 and 2, via their 
own corresponding death domains (Neumann et al. 2008). A complex known as the 
Myddosome is formed (Motshwene et al. 2009) which consists of six MyD88, four 
IRAK4 and four IRAK2 death domains in a left-handed helix formation (Lin et al. 
2010). This complex, as of yet only observed in vitro, appears to be sequentially 
formed, with MyD88 subunits oligomerising first, forming a platform allowing 
IRAK4 to bind and oligomerise followed by IRAK2 (Lin et al. 2010). As there are a 
number of MyD88 subunits involved, binding of more than one MyD88-dependent 
TLR may occur, which could allow synergistic signalling in response to varied 
stimuli (Gay et al. 2011). The regions of IRAK2 that interact with this structure are 
conserved in IRAK1 also, and it has been suggested that they may be 
interchangeable in this complex (Lin et al. 2010). IRAK4 is essential for signalling 
from TLR 7/8/9 (Yang et al. 2005) and its phosphorylation and activation of IRAK1 
induces IRAK1 to dissociate from the complex and bind to TRAF6 (Li et al. 2002) 
(Figure 1). IRAK2 appears to be more important for sustained NF-κB and MAPK 
activation (Kawagoe et al. 2008) while IRAK 1 seems to be important for TLR 7/9 
signalling to IFNα induction (Uematsu et al. 2005). IRAK proteins, with the 
exception of IRAK4, also contain at least one C-terminal domain that mediates an 
interaction with TRAF6 (Ye et al. 2002). 
TRAF6 itself mediates an interaction with a complex consisting of TGF-β activated 
kinase (TAK1) and TAK1 binding proteins 1 and 2 (TAB 1 and 2) and, following 
ubiquitination of TRAF6 and TAK1 and a series of phosphorylation steps, TAK1 is 
activated (Wang et al. 2001). TAK1 can then phosphorylate IKKβ, which activates a 
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complex known as the IKK complex, resulting in the activation of NF-κB (Figure 1, 
section:1.4).  
 
Figure 1: Overview of the main signalling pathways induced by the key anti-viral 
pattern recognition receptors. 
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1.2.1.1.3   TLR  signalling  to  IRF  activation  
All TLRs signal to NF-κB activation (Doyle & O’Neill 2006), but it is not the only 
pathway that can be induced in response to TLR stimulation. For example, MAP 
kinase kinases like MKK4 and MKK3/6 can also be activated (Moriguchi et al. 
1996), which results in p38 MAPK and JNK activation and subsequently activation 
of the transcription factor AP-1, which regulates the expression of effector cytokines 
such as IL-8 and TNFα (Zhong & Kyriakis 2007). Other key pathways that are 
induced downstream of TLRs are those that are mediated by the interferon regulatory 
factor (IRF) transcription factor family. The IRFs are important in the response to 
viruses and are responsible for the induction of a wide range of genes, especially 
those involved in mounting an anti-viral immune response, the most important of 
which, are the type 1 IFNs, IFNα and IFNβ.  
IFNs can regulate both the innate and adaptive immune responses, and are one of the 
main mediators in the defence against viral infections (van den Broek et al. 1995). 
There are three main types of interferon: Type 1, which includes 13 subtypes of IFN-
α, IFN-β, IFN-ω and IFN-τ; type 2, which only includes IFN-γ; and type 3, 
consisting of 3 subtypes of IFN-λ (Kotenko et al. 2003). Most cell types can produce 
IFN-α and IFN-β in response to viral infection, but IFN-γ is produced only by certain 
immune cells such as NK cells, CD4+ T helper 1 (Th1) cells and CD8+ cytotoxic T 
cells (Katze et al. 2002). IFN-α and IFN-β are secreted by infected cells and bind to 
interferon receptors on surrounding cells. This triggers signalling by the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, 
inducing an antiviral state in uninfected cells. This will contribute to further IFN-α 
and IFN-β synthesis, generating a positive feedback loop (Marié et al. 1998). The 
effects that IFNs have are numerous; experiments have shown that they differentially 
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regulate hundreds of genes, which are known as interferon stimulated genes (ISGs) 
(Der et al. 1998). The ISGs mediate the anti-viral effects of IFNs, with their effects 
ranging from inhibition of viral replication to production of inflammatory mediators. 
When IRF3, 5 or 7 have been activated by phosphorylation, a conformational change 
occurs which exposes their IRF association domain that is normally masked by an 
autoinhibitory domain (Chen & Royer 2010). This allows them to homo- or hetero-
dimerise with another IRF (Barnes et al. 2003; Lin et al. 2000), translocate into the 
nucleus and, along with co-activators such as CBP and NF-κB, induce type 1 IFN. 
Each IRF induces a different set of genes depending on the cellular context (Barnes 
et al. 2004). IRF7 is one of the most important IRFs in the context of antiviral 
immunity along with IRF3 and IRF5. IRF3 is constitutively expressed while IRF7 is 
present at very low levels in all cells except pDCs, with a half-life of approximately 
5 hours (and IRF3 with a half-life of greater than 60 hours) (Prakash & Levy 2006). 
In the early phase of an anti-viral response, IFNβ and IFNα4 are produced which 
form a positive feedback loop, further inducing production and activation of IRF7, 
which will itself go on to induce more IFNβ along with IFNα1,2,4,5 (Sato et al. 
2000; Marié et al. 1998). However in the case of IRF7-IRF5 heterodimers this 
appears to be inhibitory for IFNα induction (Barnes et al. 2003). 
IRF7 is involved in both IFNα and IFNβ expression, with IFNα4 being dependent on 
IRF7 and independent of IRF3, while IRF3 is mainly involved in controlling IFNβ 
(Sato et al. 2000). The IFNB promoter contains binding sites for NF-κB, IRF3/7 and 
ATF2/c-Jun. Stimulation of IFNβ induction requires both IRF3/7 and NF-κB 
activation which form an enhanceosome along with CBP/p300, ATF2/c-Jun and 
IRF1, that binds to the IFNB promoter in non-activated cells (Merika et al. 1998). 
The promoters of IFNA subtypes however do not contain NF-κB binding sites (Raj et 
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al. 1991), but have multiple sites that can be bound by IRF family members (Chelbi-
Alix et al. 2007).  
The activation of the IRFs can occur in a number of different ways, however, the 
best known pathway to IRF3/7 activation is via the kinases TBK1 and IKKε 
downstream of TLR3/4 (TRIF dependent pathway). IKKε and TBK1 are positioned 
at a convergence point downstream of a number of PRRs, including TLRs, RLHs 
and DNA receptors (Thompson et al. 2011) (Sections: 1.2.1.2, 1.2.1.3) (Figure 1). 
These two kinases can phosphorylate IRF3 on serine 396 inducing it to dimerise and 
translocate to the nucleus to induce type 1 IFN (Fitzgerald, McWhirter, et al. 2003) 
(Figure 1). TRAF3 is thought to function as the link between TLRs and IRF 
activation through interactions with regulatory kinases such as TBK1, IKKε and 
IRAK1 (Oganesyan et al. 2006). While IKKε and TBK1 act as positive regulators of 
these pathways IRAK1 appears to be a negative regulator, it has been shown that the 
phosphatase SHP-1 promoted type 1 IFN induction by inhibiting IRAK1 (An et al. 
2008). It has more recently been demonstrated to be an IKKε regulator, where it acts 
to limit TAK1-IKKβ-NF-κB signalling downstream of TLR3 (Bruni et al. 2013).  
There are however, reports of IKKε/TBK1 activation independent of TRAF3 in a 
Myd88-dependent pathway (Clark et al. 2011). The mechanism of activation of the 
IRF proteins downstream of TLR7/8/9 specifically in pDCs has not yet been 
revealed fully and is not nearly as well elucidated as the TRIF-dependent pathway. 
However it appears that the key kinases downstream of these receptors are IKKα, 
NIK and IRAK1 and not IKKε and TBK1. The importance of these kinases along 
with a more detailed discussion of TLR 7/8/9 signalling can be found in section 1.3. 
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1.2.1.2 RIG-­‐I  like  Helicases  
The RIG-like family of RNA helicases are a key example of helicases being 
involved in innate immunity and belong to the SF2 helicase superfamily. The three -
known members are: retinoic acid-inducible gene I (RIG-I, DDX58) melanoma 
differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 
2 (LGP2, DHX58).  Homologues of the RIG-family members are found in many 
different species and appear to be highly conserved in vertebrates (Zou et al. 2009). 
The family is named after the RIG-I protein itself, which was initially described to 
bind double-stranded RNA, an intermediate in the replication of a wide range of 
viruses, and to induce activation of IRF-3 and NF-κB (Yoneyama et al. 2004). It was 
discovered in a screen for factors that enhanced IFN-β induced by the dsRNA 
analogue poly(I:C) (Yoneyama et al. 2004).  Following on from this, MDA5 and 
LGP2 were both identified by database searches for proteins showing a high amino 
acid identity with RIG-I (Yoneyama et al. 2004). Both RIG-I and MDA5 possess 
two CARD domains at their N-terminus which are involved in downstream 
signalling as it allows them to interact with the mitochondrial CARD-domain 
containing molecule MAVS (Seth et al. 2005). LGP2 however lacks the CARD 
domains and is thought to regulate both RIG-I and MDA5. Its exact function is still 
unclear as there are reports suggesting that it acts as both an inhibitor (Rothenfusser 
et al. 2005) and enhancer of the other two RLHs (Satoh et al. 2010).  All three RLHs 
possess domains involved in the specific recognition of dsRNAs (Cui et al. 2008; 
Takahasi et al. 2009). RIG-I ligands include RNA possessing a 5’triphosphate 
followed by a short double stranded region (forming a panhandle like structure) 
(Schlee et al. 2009), and potentially, long dsRNA lacking the 5’triphosphate end 
(Binder et al. 2011). MDA5 and LGP2 are not as well characterised but it is thought 
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that they are involved in dsRNA recognition also. MDA5 has been described to 
recognise mRNA lacking 2’-O methylation (Züst et al. 2011) and branched dsRNA 
(Pichlmair et al. 2009). MDA5 and LGP2 bind dsRNA, but unlike RIG-I this binding 
is independent of the presence of 5’triphosphates (Pippig et al. 2009). The 
downstream pathway that is induced by the RLHs can result in activation of 
IKKε/TBK1, leading to IRF3/7 activation and induction of type 1 interferon 
(Section: 1.2.1.1.3) (Figure 1).  
1.2.1.3 DNA  Receptors  
The receptors that recognise DNA are as of yet poorly characterised compared to the 
more clearly established RIG-I-like and TLR receptors. The existence of such 
receptors became apparent through studies using MyD88/TRIF knockout mouse 
embryonic fibroblasts, which lack signalling from all known TLRs (Ishii et al. 2006). 
TLR9 was previously the only known receptor for DNA but signalling still occurred 
in response to certain types of DNA, even when TLR9 signalling was not present 
(Ishii et al. 2006). Like the RLHs and TLRs, most known DNA sensing pathways 
appear to converge at the level of TBK1 and IKKε. The adaptor protein, stimulator 
of interferon genes (STING), which interacts with TBK1, appears to be important in 
DNA sensing pathways (Sauer et al. 2011; Ishikawa & Barber 2008). There have 
been a number of DNA sensing receptors discovered to date including the DNA-
dependent activator of IFN-regulatory factors (DAI), RNA pol III, Leucine-rich 
repeat flightless-interacting protein 1 (LRRFIP1), and IFI16 (Unterholzner 2013). 
DAI was one of the first to be discovered and is known to recognise Z- and B- form 
dsDNA (Takaoka et al. 2007). RNA pol III transcribes B-form dsRNA to 5’-ppp 
RNA which can subsequently be recognised by RIG-I to induce a response (Chiu et 
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al. 2009). LRRFIP1 was identified in a screen that showed its knockdown resulted in 
reduced IFNβ production in response to both dsRNA and dsDNA. It appears to not 
operate through activation of IRF3 but instead it enhances activation of β-catenin, a 
transcriptional co-activator involved in IFNβ induction (Yang et al. 2010). Knock 
down of IFI16 also resulted in a reduction of an IFN response to exogenous DNA 
and HSV-1 (Unterholzner et al. 2010). There are additional putative DNA receptors 
such as DDX41, DDX9 and DDX36, but it is still unclear as to their exact roles 
(Broz & Monack 2013). Recently cGAMP synthase (cGAS) has been reported to act 
as a sensor for cytosolic DNA and to trigger IRF3 activation via cGAMP and STING 
(Wu et al. 2013; Sun et al. 2013). In addition, activation of AIM2-inflammasome 
mediated activation of caspase1 has been shown to occur in response to cytosolic 
DNA (Shah et al. 2013).  
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1.3 TLR  3/7/8/9  –  The  Anti-­‐Viral  TLRs  
The most relevant TLRs in the context of viral infection are those that are located 
within the cell, namely TLR3/7/8 and 9. These PRRs are ideally placed on 
endosomal membranes to detect viral nucleic acids from endocytosed virions after 
digestion of their viral envelope (Nishiya & DeFranco 2004), but can also detect 
actively replicating virus in the cytoplasm through an autophagy-dependent 
mechanism, where replication intermediates are transported into the lysosome (Lee 
et al. 2007). TLR9 was the first of this group to be revealed, as a receptor for CpG-
rich unmethylated DNA (Hemmi et al. 2000); and was later implicated as having a 
role in viral recognition, when it was shown to be required for IFNα secretion 
following HSV infection (Lund et al. 2003). In 2001, TLR3 was found to recognise 
double-stranded RNA (which is synthesised as part of the replication cycle of many 
viruses (Jacobs & Langland 1996)) and to activate the NF-κB and type-1 IFN 
pathways (Alexopoulou et al. 2001). TLR7 was shown to mediate the antiviral 
response induced by imidazoquinoline compounds in a MyD88-dependent manner 
(Hemmi et al. 2002) and finally, in 2004, TLR7 along with TLR8 were shown to be 
involved in the recognition of HIV-1 derived ssRNA in DCs and Macrophages (Heil 
et al. 2004). Overall, the genes induced by the antiviral TLRs greatly depend on a 
number of factors, including the particular TLR being engaged and the cell type, for 
example TLR7 induces IFNα in pDCs and IL-12 in mDCs (Ito 2002). While TLR7 
and 8 were initially thought of as being redundant, there are some differences 
emerging in their ligand specificities, cellular expression/localisation and preference 
for gene induction (Gorden et al. 2005; Cherfils-Vicini et al. 2010). A study using 
selective agonists for TLR7 and 8 showed that TLR7 agonists preferentially induced 
cytokine production from plasmacytoid DCs (pDCs), while the TLR8 selective 
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agonist activated myeloid DCs (mDCs), monocytes and monocyte-derived dendritic 
cells. The same study showed a differential profile of cytokine induction, with TLR7 
agonists inducing higher levels of IFNα and IFN inducible chemokines, and TLR8 
agonists being better at inducing proinflammatory cytokines, such as TNFα and IL-
12 (Gorden et al. 2005).  
 
Figure 2: The TLR 7/8/9 signalling pathways to NF-κB and IRF activation. 
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While the signalling pathways downstream of TLR3, the RLHs and most DNA 
receptors utilise the IKK-related kinases TBK1 and IKKε for phosphorylation of 
IRF3/7 (Sharma et al. 2003) (section: 1.2.1), TLR7/8/9 signalling is independent of 
IKKε and TBK1 and instead uses the kinases IRAK1, NIK and IKKα to activate 
IRF7 (Wang et al. 2008).  
The exact mechanisms of IRF7 activation are still not fully elucidated, however, 
IKKα appears to be a key kinase, both interacting with and phosphorylating IRF7 
(Hoshino et al. 2006). There is severely decreased IFNα production in response to 
TLR7/9 ligands in IKKα-deficient bone marrow-derived dendritic cells (BMDCs) 
(Hoshino et al. 2006). However, IKKα does not act in isolation, it is phosphorylated 
by the kinase NIK on serines 176 and 180. Phosphorylation of serine 176 on IKKα 
results in activation of IRF3/7, but phosphorylation of serine 180 appears to negate 
this effect (Wang et al. 2008) implying a key role for NIK as both a positive and 
negative regulator of IKKα activity in this pathway (See also section: 1.4.2). 
IKKβ has also recently been suggested to work cooperatively with IKKα to 
phosphorylate IRF3/7 in a TAK1 dependent manner (Pauls et al. 2012; Han et al. 
2004). Additionally IKKα has recently been shown to interact with and 
phosphorylate IRF3 also. The authors showed that serine 396 phosphorylation is not 
sufficient for optimal IRF3 activity and that an additional phosphorylation by IKKα 
enhances IRF3 interaction with the coactivator CBP (Mancino et al. 2013). IKKα 
also has a role in the phosphorylation of IRF5. However, while IRF7 activity is 
enhanced following phosphorylation by IKKα (Hoshino et al. 2006), IRF5 is 
negatively regulated as a result of this modification (Schoenemeyer et al. 2005). 
IRAK1 may play a role, as in IRAK1-/- pDCs TLR7/9 induction of IFNα was 
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completely abolished, while NF-κB or MAPK activation were unaffected (Uematsu 
et al. 2005).  
It is not yet clear if all these kinases are required for signalling to IFN induction and 
if they work cooperatively or in different contexts. The cellular context is quite 
important, as there is significant regulation of, and crosstalk between, TLRs and 
other pathways. The response upon TLR engagement can vary greatly depending on 
how the pathway is regulated. For example if a cell has received IFN signals from 
another infected cell, it is primed through the upregulation of signalling mediators 
like IRF7. Also there is a temporal aspect, the early response IFNs like IFNα4 and 
IFNβ are induced quite rapidly, while the late response IFNs IFNα 1,2,4,5 are 
produced later (Marié et al. 1998). The activity and involvement of particular 
upstream kinases may vary depending on factors such as the receptors engaged, the 
time since receptor engagement, and crosstalk from other signalling pathways. 
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1.4 NF-­‐κB  
In humans, there are 5 NF-κB family members; p50/p105 (NF-κB1), p52/P100 (NF-
κB2), p65 (RelA), RelB and c-Rel (Nabel & Verma 1993). All members contain an 
N-terminal Rel homology domain (RHD) which mediates dimerization and binding 
to promoter elements known as κB elements. In resting cells NF-κB subunits are 
retained in the cytoplasm in an inactive state by proteins known as inhibitors of NF-
κB (IκB). The 3 IκB proteins, IκBα, IκBβ, and IκBε contain ankyrin- repeat motifs, 
which mask a conserved nuclear localisation sequence found in the RHD, impairing 
the import of the NF-κB proteins into the nucleus. In addition, the precursors of p50 
and p52 (p105 and p100 respectively) also act in a similar way to the IκBs. p105 and 
p100, like the IκBs, both contain ankyrin-repeat sequences in their C-termini, which 
are lost upon their processing to p50 and p52. Activation of NF-κB can occur in a 
number of ways, most of which involve activating IKK (IκB Kinase) complexes to 
phosphorylate the IκBs and induce their degradation (or in the case of p105 and 
p100, their processing) (Beg & Baldwin 1993). Degradation of the IκBs frees the 
NF-κB subunits, allowing them to translocate into the nucleus. 
The best known pathway to NF-κB activation is the classical or “canonical” pathway 
typically associated with the activation of the p105/p50 and p65 NF-κB proteins. 
However, there is also an alternative or “non-canonical” pathway that 
characteristically results in activation of p100/52 and RelB and induces genes that 
are distinct from those induced by the canonical NF-κB pathway (Bonizzi & Karin 
2004). A hybrid pathway also exists, which involves formation of a dimer of p52 
from the alternative pathway with p65 from the canonical pathway (Wietek et al. 
2006). This requires activation of both pathways simultaneously. In this case IKKε 
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can promote p52 transactivation via its interaction with p52 and phosphorylation of 
p65 (Wietek et al. 2006).  
 
Figure 3: Overview of NF-κB activation, showing the canonical NF-κB pathway 
(left), the “hybrid” pathway (centre) and the alternative NF-κB signalling pathway 
(right). 
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The genes that are upregulated by NF-κB activation include TNFα (Shakhov et al. 
1990), IL-1α (Mori & Prager 1996), IL-6 (Son et al. 2008), BAFF (Moon & Park 
2007), IL-17 (Shen et al. 2006), lymphotoxin-α (Worm et al. 1998), RANTES 
(Moriuchi et al. 1997), Cyclin D1(Guttridge et al. 1999), and IRF7 (Lu et al. 2002). 
Indeed the genes affected by NF-κB are numerous and varied as it is involved in the 
regulation of a number of cellular processes, including apoptosis, adhesion, 
proliferation, stress response, innate and adaptive immunity and tissue remodelling 
(Perkins 2007). As a central mediator in such a wide range of cellular processes it is 
tightly regulated with many other pathways modulating the outcome of its activation 
(Perkins & Gilmore 2006). 
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1.4.1 Canonical  NF-­‐κB  Pathway  
The canonical IκB kinases IKKα and IKKβ are best known for their involvement in 
the canonical NF-κB activation pathway (Mercurio 1997), in which they form the 
IKK complex along with the regulatory subunit IKKγ (NEMO). The IKK-complex, 
once activated by Lys63-linked ubiquitination of NEMO by TRAF6 and subsequent 
activation of IKKα/β by recruitment of other kinases such as TAK1, will 
phosphorylate the inhibitory IκB bound to NF-κB subunits. In addition to this typical 
role for the IKKs, both of these kinases have been implicated in other NF-κB 
regulation activities, such as the direct phosphorylation of NF-κB subunits. NF-κB 
phosphorylation, for example the phosphorylation of p65 on serine 536 (Sakurai 
1999) or serine 468 (Mattioli et al. 2006), is important for activating the transcription 
activity of the NF-κB subunits.  
1.4.2 The  Alternative  NF-­‐κB  Pathway  
IKKα, in addition to its role in canonical NF-κB signalling is also involved in the 
non-canonical NF-κB pathway. This non-canonical pathway has been shown to be 
important in a range of physiological functions, including the development of 
secondary lymphoid organs, bone metabolism, survival and maturation of B-cells 
and thymic deletion of autoimmune T-cells (Sun 2012). As such, lymphoid 
malignancies (Yu et al. 2012), osteoporosis (Seo et al. 2012), and autoimmune 
disorders (Brown et al. 2008) are just some of the diseases that have been associated 
with disregulation of this important signalling pathway. 
The non-canonical pathway is typically activated by stimulation of CD40, 
lymphotoxin-β receptor (LTβR) (Müller & Siebenlist 2003) or B-cell activating 
factor of the TNF family receptor (BAFFR) (Claudio et al. 2002), among other 
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receptors (Sun 2011). LTβR is most highly expressed in lymphoid and epithelial 
cells and has been shown to also play a role in homeostasis of dendritic cells (De 
Trez 2012). LTβR has two ligands, lymphotoxin (including LTα and LTβ) and 
LIGHT (homologous to LT, inducible expression, competes with herpes simplex 
virus (HSV) glycoprotein D for HSV entry mediator (HVEM), a receptor expressed 
on T lymphocytes). CD40 is found on a wide variety of cell types including dendritic 
cells, B-cells, monocytes, neurons, fibroblasts and endothelial cells (Chatzigeorgiou 
et al. n.d.). The ligand for CD40 is CD154, which is expressed by activated T-cells, 
while BAFFR is found on B-cells and has BAFF as its ligand (Kayagaki et al. 2002). 
All three of these receptors possess TRAF binding motifs, which allows their 
interaction with different TRAF proteins, including TRAF3 and 2. However, while 
LTβR and CD40R can bind both TRAF2 and 3 (Sanjo et al. 2010; Werneburg et al. 
2001), BAFFR can bind TRAF3 but not 2 (Morrison et al. 2005). 
A key step in the alternative NF-κB pathway is the proteasome-mediated processing 
of the NF-κB protein p100 into p52. NIK is an essential component in the alternative 
NF-κB pathway, as all known pathways that induce p100 processing involve NIK 
(Sun 2010; Xiao et al. 2001). In unstimulated cells NIK is present at a very low 
level, which is due to its constitutive degradation mediated by TRAF3 (Liao et al. 
2004). TRAF3, which is also involved in signalling downstream of TLR7/8/9 
(Figure 2), bridges an interaction between NIK and TRAF2, which itself interacts 
with cIAP1/2. The roles of cIAP1 and 2 seem to overlap greatly, but their role in 
repression of NF-κB activation may depend on cell type (Giardino Torchia et al. 
2013). The TRAF3-TRAF2-cIAP1/2 forms an E3 ligase complex resulting in K48-
linked ubiquitination of NIK, thereby targeting it for degradation by the proteasome 
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(Liao et al. 2004; Zarnegar et al. 2008). In this way, the pathways regulated by NIK 
are kept suppressed by ensuring NIK levels are as low as possible.  
Removal of this suppression is achieved yet again by controlling degradation of a 
protein, in this case TRAF3. TRAF3 degradation results in stabilisation of NIK 
levels, which means that induction of this pathway is dependent on de novo synthesis 
of NIK protein (Liang et al. 2006). When one of the alternative NF-κB-inducing 
receptors is stimulated, they bind TRAF3 and/or TRAF2 via their TRAF binding 
motif, which recruits the whole E3 complex to the receptor. This changes the target 
of the cIAP ligases from NIK to TRAF3, resulting in its degradation 
(Vallabhapurapu et al. 2008). With TRAF3 levels being reduced, this means that 
NIK can no longer be recruited to the TRAF2-cIAP1/2 complex. 
NIK is unable to induce p100 phosphorylation alone but instead operates with IKKα. 
While NIK is known to phosphorylate and activate IKKα (Ling et al. 1998), it also 
promotes the interaction of IKKα with p100 independent of its kinase activity (Xiao 
et al. 2004). The phosphorylation of IKKα on serines 176 and 180 by NIK activates 
IKKα (Senftleben et al. 2001) and is required for its induction of p100 processing 
(Wang et al. 2008). However this is in contrast to IKKα regulation downstream of 
TLR7/8/9, where phosphorylation of these two serines shows different effects 
(Section: 1.3). NIK therefore, in addition to activating IKKα, seems to regulate IKKα 
activity. When serine 176 is phosphorylated, IKKα is primarily involved in IRF3/7 
activation, but a further phosphorylation on serine 180 inhibits this and switches 
IKKα to be involved in the alternative NF-κB pathway (Wang et al. 2008). IKKα 
homodimers will then phosphorylate p100, which results in p100 being ubiquitinated 
and subsequently processed by the 26S proteasome to p52. NIK promotion of IKKα 
binding to p100 requires serines 866 and 870 of p100 (Xiao et al. 2004). Mutation of 
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these residues does not appear to reduce NIK binding to p100 but abolishes IKKα 
binding. IKKα phosphorylates a number of residues in p100 including serines 99, 
108, 115, 123, 872. The mutation of these serines ( also including serines 866 and 
870) results in reduced processing of p100 to p52 by stopping recruitment of β-TrCP 
(β-Transducin repeat Containing Protein) (Xiao et al. 2004), the ubiquitin ligase that 
ubiquitinates p100 and thereby marks it for processing.  
Following this processing, p52, as it possesses no transactivation domain (TAD) of 
its own, needs to dimerise with an NF-κB subunit possessing a TAD (typically RelB) 
to activate gene expression. The dimerised pair of NF-κB subunits translocate into 
the nucleus to induce specific gene transcription, for example genes involved in cell 
cycle progression like skp2 (Schneider et al. 2006) and genes involved in 
development of lymphoid organs (Senftleben et al. 2001). However, activated NF-
κB also needs to recruit co-activators to induce gene expression. Co-activators like 
CREB-binding protein (CBP) or p300 are involved in enhancing the activities of 
many transcription factors, like STATs, IRFs and NF-κB. 
There are still some unanswered questions about the exact mechanism by which 
IKKα and NIK induce p100 degradation. For example it is unclear whether NIK 
needs to be activated and whether any other proteins are involved in this activation. 
Elucidating the exact mechanisms of how NIK is activated and p100 processing is 
regulated may provide key insights into a number of disorders, as disregulation of 
the alternative NF-κB pathway is associated with a range of diseases (Sun 2011). 
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1.5 DExD/H-­‐box  RNA  Helicases  
Helicases are ATP-driven enzymes which unwind or remodel double-stranded DNA 
or RNA (Wu 2012); they are involved in nearly every aspect of nucleic acid 
metabolism (Pyle 2008). Based on their substrates they can be broadly separated into 
two groups - RNA and DNA helicases, however there are some helicases that can act 
on both (Wu 2012), and as such the family groupings of helicases are a bit more 
complex. 
There are several superfamilies of helicase proteins, the main accepted groupings are 
the SF1, SF2 and SF3 superfamilies, however there is some debate over the group 
divisions (Gorbalenya & Koonin 1993; Fairman-Williams et al. 2010; Singleton et 
al. 2007). The SF1 and SF2 super families have similar conserved motifs but are 
distinct from each other; it has been suggested that they may share a common 
ancestor (Fairman-Williams et al. 2010; Gorbalenya et al. 1989). The SF3 
superfamily consists of viral helicases from small DNA or RNA viruses which only 
contain 3 conserved motifs (including the Walker A and B motifs found in all 
helicases) (Hickman & Dyda 2005). The families comprise proteins from archaea, 
eubacteria, eukaryotes and viruses and have varying substrate specificity and 
unwinding activity. The grouping of these families is due to highly conserved 
regions in their sequences which are shared between all members of one particular 
family (Caruthers & McKay 2002). For example the DEAD-box family of RNA 
helicases are characterised by nine conserved motifs (Figure 4). 
 
Figure 4 The nine motifs typical of DEAD-box helicases (Cordin et al. 2006).  
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The DEAD-box family of putative RNA helicases belongs to the SF2 superfamily 
and is closely related to, but distinct from, the RIG-like helicases (Section: 1.2.1.2) 
(Gorbalenya & Koonin 1993). The family was first identified in 1989 by systematic 
sequence analysis of proteins containing a purine NTP binding motif (Linder et al. 
1989). This new family consisted of 25 confirmed or suspected helicases and shared 
a number of conserved regions in their sequence. The 9 conserved motifs that 
characterise the DEAD box family are the Q-motif, motif 1 (Walker A motif), motif 
1a, motif 1b, motif II (Walker B motif), motif III, motif IV, motif V, and motif VI 
(Figure 4 and  
Table 2) (Cordin et al. 2006). The name for this family is derived from motif II, 
which contains the amino acid sequence D-E-A-D. 
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Table 2 The typical motifs of DEAD-box helicases and their function. An 
example of motifs used to classify a helicase family. C= charged group (D, E, H, K 
or R), o = alcohol (S or T) (Cordin et al. 2006).   
MOTIF 
NAME 
AMINO ACID 
SEQUENCE 
FUNCTION REFERENCE 
Q-Motif F-16aa-GFccPoPIQ-
16 aa-motif I 
Regulate ATP Binding and 
Hydrolysis 
(Tanner et al. 
2003; Tanner 
n.d.) 
I (Walker A 
motif) 
AxxGxGKT ATP Binding 
MgATP/MgADP binding 
 
Ia PTRELA Unknown (possibly RNA 
binding) 
(Caruthers & 
McKay 2002; 
Fuller-Pace 
1994) 
Ib TPGR Unknown  
ll (Walker B 
motif) 
DEAD ATP Hydrolysis 
MgATP/MgADP binding 
(Caruthers & 
McKay 2002; 
Fuller-Pace 
1994) 
III SAT ATP Hydrolysis/RNA 
Unwinding 
(Fuller-Pace 
1994) 
IV LIV Unknown  
V ARGID Unknown  
VI HRxGRxGR ATP Hydrolysis/RNA Binding (Fuller-Pace 
1994) 
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Structures of various helicases of the SF1 and SF2 families have been shown to be 
almost identical within the RecA like core structure, which is a very highly 
conserved structural fold found in ATPases (Caruthers & McKay 2002; Johnson & 
McKay 1999). However, it is the surrounding unconserved C- and N-terminal 
domains that confer differences in substrate specificity and activity, possibly 
providing different binding domains, regulating enzyme activity or even allowing 
oligomerisation of the helicase (Fairman-Williams et al. 2010).  
All helicases have the Walker A and B motifs, which are the most highly conserved 
regions and are involved in ATP binding and hydrolysis. They are located in a cleft 
that is formed between the two RecA-like globular domains. The Walker A motif is 
part of a classical phosphate-binding loop (P loop), which is commonly found in 
many proteins and is involved in binding and hydrolysing nucleoside triphosphates 
and ensures the triphosphate moiety is positioned correctly (Leipe et al. 2002). The 
Walker B motif has an aspartic acid, which is involved in Mg2+ binding and 
functions with the Walker A and Q motifs to help bind and hydrolyse ATP (Walker 
et al. 1982). The motifs involved in binding nucleic acid are the 1a, 1b, IV and V 
motifs and are situated on the opposite side to the NTP binding site (Fairman-
Williams et al. 2010). 
In addition to their roles in unwinding of nucleic acid structures, there is increasing 
evidence that helicase proteins perform functions that may be independent of their 
helicase properties (Fuller-Pace 2006; Schröder et al. 2008; Soulat et al. 2008), like 
involvement in transcriptional regulation (Fuller-Pace & Nicol 2012) or in innate 
immunity (section :1.5.1).  
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1.5.1 Helicases  in  Innate  Immunity  
Several helicases in the DExD/H-box family have been shown to be involved in the 
innate immune response to viruses including members of the DEAD, DEAH, DExD, 
and DExH (including RLHs) helicase families (Fullam & Schröder 2013). They have 
been implicated as sensors for viral nucleic acids as well as being involved in 
downstream signalling events. However, a number of helicases potentially play a 
dual role in this system: in addition to being involved in the innate anti-viral 
response itself, there are helicases that are also essential host factors needed by some 
viruses to support or enhance their own replication. While the RIG-like helicases 
(DExH family) are well known to be one of the most important groups of PRRs and 
are established as having a role in innate immune signalling (Schmidt et al. 2012) 
(section: 1.2.1.2), a few other members of the DExD/H family members have more 
recently been implicated as having roles in innate immunity too (Zhang, Yuan, Lu, et 
al. 2011; Zhang, Yuan, Bao, et al. 2011; Zhang, Kim, et al. 2011; Miyashita et al. 
2011; Oshiumi, Sakai, et al. 2010; Kim et al. 2010), one of which is DDX3 
(Schröder et al. 2008; Gu et al. 2013).  
1.5.1.1 DDX3  
DDX3 is a member of the DEAD-box helicase family. It is a 662 amino acid protein 
that is universally expressed in a wide range of human tissues (Kim et al. 2001). It 
has two homologues: DDX3X and DDX3Y, that were first described in 1997 in a 
study of the non-recombining region of the Y chromosome: DDX3X (hereafter 
referred to as DDX3) was one of several genes that escaped X-inactivation (Lahn 
1997). DDX3 contains the 9 motifs that are characteristic of the DEAD-box RNA 
helicases (Linder et al. 1989) and as such, was placed in the family (Figure 5).  
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MSHVAVENALGLDQQFAGLDLNSSDNQSGGSTASKGRYIPPHLRNREATKGFYDKDSSGW 
SSSKDKDAYSSFGSRSDSRGKSSFFSDRGSGSRGRFDDRGRSDYDGIGSRGDRSGFGKFE 
RGGNSRWCDKSDEDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIE 
SFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILS 
QIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVV 
YGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQ 
IRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVV 
WVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDR 
EEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGL 
ATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSSRGRSKSSRFSGGFGAR 
DYRQSSGASSSSFSSSRASSSRSGGGGHGSSRGFGGGGYGGFYNSDGYGGNYNSQGVDWW 
GN 
Figure 5 Sequence of DDX3 showing 9 conserved motifs highlighted in red with the 
D-E-A-D motif in yellow (Cordin et al. 2006; Ota et al. 2004). 
 
Since its initial discovery, DDX3 has been implicated in almost all aspects of RNA 
metabolism, including unwinding, splicing, import/export, transcription, translation 
and ribosome assembly (Schröder 2010; Geissler et al. 2012). Additionally, DDX3 
has been suggested as having a role in the cell cycle (Chang et al. 2006; Choi & Lee 
2012) and there have been several reports indicating an association with cancer 
progression (H. Liu et al. 2012; Sun et al. 2011). However, its exact function in this 
process is still unclear, as it has been suggested to be both a tumour suppressor 
(Chao et al. 2006; Wu et al. 2011; Chang et al. 2006) and an oncogene (Botlagunta et 
al. 2008; Botlagunta et al. 2011). In addition to these roles it has also been shown to 
be important in host responses to viral infection. 
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1.5.1.1.1 Role  of  DDX3  in  Innate  Anti-­‐Viral  Immune  Signalling  
Two simultaneous reports in 2008 provided the first evidence of DDX3 being 
involved in innate immune signalling pathways (Schröder et al. 2008; Soulat et al. 
2008). The first identified DDX3 as a molecular host target of the vaccinia virus K7 
protein. K7 inhibited Ifnb induction at the level of IKKε and TBK1, the two key 
kinases that are a point of convergence for TLR3/4 and the RLHs, and which 
phosphorylate and activate the transcription factors IRF7 and IRF3 that are required 
for type I IFN induction (Section: 1.2.1.1.3). In a search for K7-interacting proteins 
DDX3 was found. Further investigation showed that DDX3 interacts with IKKε after 
Sendai Virus stimulation and enhances induction of the Ifnb promoter. K7 was 
shown to block key residues of DDX3 possibly preventing its interaction with IKKε 
(Oda et al. 2009). The intrinsically unstructured N-terminal region of DDX3 was 
shown to be required for this activity, but it was independent of the ATPase and 
unwinding activities of DDX3. Additionally, exogenous expression of DDX3 aa 1-
139 could act as a dominant negative to wt DDX3 (Schröder et al. 2008). The second 
report concurrently revealed that DDX3 interacts with, and is a phosphorylation 
target of, TBK1 (Soulat et al. 2008). TBK1 and DDX3 synergistically enhanced Ifnb 
induction, and DDX3 had to be phosphorylated by TBK1 for this synergism to 
occur. This report also supported a role for DDX3 in Ifnb promoter induction 
downstream of TBK1/IKKε. However, these authors also demonstrated that DDX3 
is recruited to the Ifnb promoter enhancer region using chromatin 
immunoprecipitation (Soulat et al. 2008). Studies on HBV polymerase (pol) 
corroborated these results, showing that HBVpol inhibits type 1 IFN induction by 
preventing the DDX3 – IKKε/TBK1 interaction (Yu et al. 2010; Wang & Ryu 2010). 
DDX3 also seems to have a role in the response to dsDNA viruses, for example 
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HCMV (Human Cytomegalovirus), which is recognised by the cytoplasmic DNA 
receptor DAI (DNA-dependent Activator of IRFs) independent of MAVS. The IFNβ 
induction that is observed in response to this virus is greatly diminished upon 
knockdown of DDX3, further implicating it in the pathways to IFN production 
(DeFilippis et al. 2010). DDX3 has also been shown to be in a complex with RIG-I 
and MAVS. It has been suggested that DDX3 can act jointly with RIG-I and mda5 as 
a sensor for viral RNA and that it may induce IFNβ at the early stages of infection 
until sufficient RIG-I has been synthesised and can then take over viral recognition 
(Oshiumi et al. 2010). 
The numerous reports that have been published implicating DDX3 in pathways 
leading to type-1 interferon induction, provide compelling evidence for its role in the 
innate immune response to viruses. However, despite the strength of the evidence the 
exact nature of DDX3’s mechanism of action is not clear yet and its placement in the 
pathway is subject to some dispute as some of the data are contradictory. DDX3 has 
been suggested to act as a PRR at the early stages of infection (Oshiumi et al. 2010). 
It has also been implicated as being a key downstream mediator in the pathway, 
interacting with both IKKε and TBK1 and enhancing their action (Schröder et al. 
2008; Soulat et al. 2008). Finally, it has also been shown to be bound to the Ifnb 
promoter directly, suggesting a role in transcriptional regulation, possibly acting as a 
transcription factor (Soulat et al. 2008). While the majority of evidence points to the 
interaction of DDX3 with IKKε/TBK1 as being its most important of these roles in 
the pathways, DDX3 may have multiple functions, adapting its role in response to 
differing conditions within the cell. 
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1.5.1.1.2 Role  of  DDX3  in  Viral  Replication  
In the years following the initial description of the DDX3X gene, a number of 
reports have shown that several viruses target DDX3 and/or use it for their own 
benefit (Owsianka & Patel 1999; Yedavalli et al. 2004; Krishnan & Zeichner 2004; 
Ariumi et al. 2007; Ishaq et al. 2008; Jorba et al. 2008). In fact, it has been shown 
that Human Immunodeficiency Virus 1 (HIV-1) and Hepatitis C Virus (HCV) 
require DDX3 as an essential part of their replication cycle (Ariumi et al. 2007; 
Yedavalli et al. 2004; Randall et al. 2007).  
In the case of HIV-1, DDX3 has been shown to be required for the export of 
unspliced and partially spliced HIV-1 RNA out of the nucleus. HIV-1 exports its 
incompletely spliced Rev Responsive Element (RRE) containing RNAs out of the 
nucleus via a Chromosome Maintenance Region 1 (CRM1)-mediated pathway 
(Yedavalli et al. 2004). CRM1 exports proteins that contain a leucine rich NES 
(Nuclear Export Signal) and can also export small nuclear RNAs and ribosomal 
RNA. This pathway apparently also requires DDX3, which was shown to bind to 
HIV-1 rev and CRM1, thereby facilitating export of RRE-containing HIV-1 RNAs 
out of the nucleus. It suggested that DDX3 is an effector of CRM-1 mediated 
transport rather than cargo as neither RanGTP binding nor its NES are required for 
DDX3 binding to CRM1 (Yedavalli et al. 2004). DDX3 binding to CRM1 does 
however seem to be dependent on its helicase activity, suggesting that RNA 
unwinding plays a role. Due to its requirement for HIV-1 replication, several studies 
have attempted to develop inhibitors for DDX3 that could potentially be used 
therapeutically against HIV-1. There have been several reports of groups attempting 
to target DDX3 to block HIV-1 replication using either shRNAs (Ishaq et al. 2008) 
or small molecule inhibitors (Yedavalli et al. 2008; Maga et al. 2008; Radi et al. 
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2012). Depletion of endogenous DDX3 using shRNA inhibited the export of HIV-1 
RNAs and suppressed the replication of the virus while not affecting cell viability 
(Ishaq et al. 2008). Another group developed ring expanded nucleoside (REN) 
analogues that inhibited the ATP-dependent activities of DDX3, this also suppressed 
HIV-1 replication while still being non-toxic to the cells (Yedavalli et al. 2008). Yet 
another small molecule inhibitor was developed that can inhibit both the ATPase 
activity and the helicase functions of DDX3 (Radi et al. 2012). The emergence of 
resistance to antiretroviral drugs is a significant problem for HIV-1 treatment today. 
It is thought that targeting essential host factors of viral replication could be a better 
strategy, as the virus should find it harder to evolve ways of escaping these 
treatments (Kwong et al. 2005).  
Several studies have shown that the HCV Core protein interacts with DDX3 
(Owsianka & Patel 1999; Mamiya & Worman 1999; You et al. 1999) and  that 
DDX3 is required for HCV replication (Ariumi et al. 2007; Randall et al. 2007). 
HCV contains both structural and non-structural proteins; HCV Core protein is one 
of the structural proteins. It, along with two envelope glycoproteins, forms the viral 
nucleocapsid (Owsianka & Patel 1999). The core protein was shown to disrupt the 
interaction between MAVS and DDX3 and to thereby block the induction of anti-
viral IFNβ (Oshiumi et al. 2010). However in contrast, another study suggested the 
Core protein can induce IFN via DDX3 (Kang et al. 2012). In DDX3 knockdown 
studies a decrease in HCV RNA accumulation (80-90%) and colony formation was 
observed (Ariumi et al. 2007). Surprisingly, however, it is not the HCV Core 
interaction that causes this dependence. In a study that mutated a key residue in the 
HCV Core protein that abrogated the interaction with DDX3, no observable 
difference in viral replication or RNA accumulation was observed (Angus et al. 
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2010). The question as to why DDX3 is required for HCV replication therefore 
remains to be answered. HCV might have a dual effect in targeting DDX3, it uses 
DDX3 to enhance its replication, while simultaneously suppressing its antiviral role. 
Hepatocellular carcinoma (HCC) is a highly prevalent cancer in the modern world 
and is linked with hepatitis virus infection (Alter 2007). In the analysis of human 
HCC tumour samples, DDX3 was down regulated in HCC samples from Hepatitis B 
Virus (HBV) positive patient samples, while no down-regulation was observed in 
those that were HCV positive (Chang et al. 2006). The same study linked DDX3 to 
the progression of the cancer with the observation that knock-down of DDX3 led to 
early entry into S-phase and an increased growth rate. Knockdown of DDX3 also 
resulted in an increase in cyclin D1 and a concurrent decrease in p21(waf1) both of 
which are cell cycle regulators (Chang et al. 2006). This deregulation in cell growth 
may enhance HBV’s rate of replication and contribute to cancer progression. 
Another advantage for HBV to have DDX3 downregulation is due to the observation 
that HBV reverse transcription is inhibited by DDX3. A study by Wang et al. (2009) 
showed that DDX3 interacts with HBV pol, gets incorporated into nucleocapsids and 
inhibits viral reverse transcription. HCV, instead of downregulating DDX3 levels, 
seems to use its Core protein to disable some of DDX3’s functions, as described 
above. Recent studies have also shown a requirement for DDX3 in the replication of 
additional viruses including noroviruses (Vashist et al. 2012) and West-Nile Virus 
(Chahar et al. 2013), further demonstrating it importance for the replication of a 
range of different viruses. 
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DDX3 is a remarkable example of the multifunctional nature of RNA helicases. In 
addition to its expected roles in various different aspects of RNA metabolism, it has 
also been shown to participate in anti-viral innate immune signalling. It is most 
interesting that DDX3 is also ‘hijacked’ by certain viruses to their own end, to the 
extent that it is an essential host factor for the replication of some viruses, such as 
HIV-1 and HCV. It has been suggested as a drug target in the treatment of viral 
infection (Kwong et al. 2005). However as studies have shown the multifunctional 
roles of DDX3 as both an inhibitor and an enabler of viral infection, and due to its 
possible involvement in tumorgenesis, it is vital that we understand more about its 
mechanism of action before it can be targeted safely.  
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1.6 Aims  of  this  Study  
The fact that DDX3 is manipulated by a number of viruses and the discovery of its 
role in anti-viral innate immune signalling emphasises its importance in viral 
infection and invites further investigation. While previous studies have shown that 
DDX3 is involved in pathways mediated by the kinases IKKε (Schröder et al. 2008)  
and TBK1 (Soulat et al. 2008) and work in our lab has shown that DDX3 directly 
interacts with IKKε and enhances its autophosphorylation (Gu et al. 2013), we asked 
whether DDX3 is also involved in pathways that are independent of these two 
kinases. While most of the main innate anti-viral signalling pathways to IFN 
induction signal via IKKε and TBK1, they have been shown to be dispensable for 
one of the most important IFN inducing pathways, namely the one triggered by TLR 
7, 8 or 9 engagement (Hoshino et al. 2006) as they induce large amount of IFN upon 
recognition of viral nucleic acid. However, two other kinases that are closely related 
to IKKε and TBK1, NIK and IKKα, are involved instead. Therefore we aimed to 
investigate whether there was any involvement of DDX3 in the regulation of IKKα 
activity in a similar manner to what the lab had shown for IKKε (Schröder et al. 
2008; Gu et al. 2013). 
Therefore, in carrying out this work we aimed to: 
• Investigate a possible interaction between DDX3 and IKKα or NIK. 
• If an interaction exists, investigate the effects this interaction has on both 
proteins. 
• If an effect is present, investigate what outcome this may have on pathways 
that are regulated by IKKα and NIK. 
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Both IKKα and NIK are involved in two key immune signalling pathways, the 
alternative NF-κB pathway and TLR 7/8 signalling to IFN production (Figure 6). In 
the TLR 7/8 signalling pathway. IKKα as been shown to interact with and 
phosphorylate IRF7, IRF3 and IRF5 (Hoshino et al. 2006; Wang et al. 2008; 
Mancino et al. 2013), key transcription factors in the anti-viral innate immune 
response. In the alternative NF-κB pathway NIK and IKKα have been shown to be 
involved in the induction of p100 processing to p52 (Xiao et al. 2004; Senftleben et 
al. 2001; Wang et al. 2008), a transcription factor known to be involved in lymphoid 
organ development, bone metabolism, survival and maturation of B-cells and thymic 
deletion of autoimmune T-cells (Sun 2012). However, while the involvement of 
these two kinases in activation of these important immune signalling pathways is 
clear, the full mechanisms of how they exert their effects is not yet known. Therefore 
in this study we also sought to gain further insight into the mechanisms that these 
kinases use to induce downstream signalling.  
61 
 
 
Figure 6: IKKα is a key kinase involved in both the alternative NF-κB pathway and 
TLR 7/8/9 signalling to IFN activation. 
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2 Materials  And  Methods  
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2.1 Standard  Laboratory  Procedures  
Good laboratory practices were followed in all activities. All the tissue culture 
materials and reagents were kept sterile and used in a Class II (laminar flow) 
biological safety cabinet. Recipes for all reagents used are in appendix. 
2.2 Cell  Culture  
HEK293T cell lines were cultured in Dulbecco's Modified Essential Medium 
(DMEM) (Invitrogen) supplemented with 10% (v/v) foetal calf serum (FCS)  
(Thermo Fisher Scientific) and antibiotics (10 µg/ml gentamicin (Sigma). Cells were 
maintained at 37°C at 5% CO2 in a humidified atmosphere. Confluent cultures were 
passed at 1:10 ratio for HEK293T in T 75cm2 tissue culture flasks (Corning) every 
2-3 days. Cells were dissociated using 5% (w/v) trypsin-EDTA solution (Sigma) and 
resuspended in DMEM. 
Cells Description Selection 
Antibiotic 
HEK293T Immortalised Human embryonic kidney cell 
line, containing the SV40 Large T-antigen 
N/A 
HEK293 R1 Immortalised Human embryonic kidney cell 
line, stably transfected with IL-1R1 
N/A 
HEK293-TLR7 Immortalised Human embryonic kidney cell 
line, stably transfected with TLR7 
G418 
HEK293-TLR8 Immortalised Human embryonic kidney cell 
line, stably transfected with TLR8 
Blasticidin 
HEK293-NSC Immortalised Human embryonic kidney cell 
line, stably transfected with a random non-
silencing shRNA control 
Puromycin 
HEK293-shDDX3 Immortalised Human embryonic kidney cell 
line, stably transfected with a doxycycline  
inducible shRNA directed towards DDX3 
Puromycin 
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2.2.1 Long  term  storage  of  cells  
Cells were frozen down at a density of 1x106 cells/ml in FCS containing 10 % v/v 
DMSO (Sigma-Aldrich). Cells were pelleted by centrifugation at 1400 g and re-
suspended in freezing medium at a concentration of 1x106 cells/ml. Cells were then 
transferred to cryotubes (Nunc), placed into a chamber which allowed the 
temperature to drop at a rate of 1oC/min in a -70°C freezer for 24 hours and then into 
liquid nitrogen. 
Cells were recovered by thawing quickly at 37 °C and then added to warm complete 
culture medium; they were then centrifuged in order to remove the freezing medium. 
The cell pellet was re-suspended in warm medium and transferred to a sterile tissue 
culture flask. 
2.2.2 Transfection  
Cells were transfected with plasmids using either Calcium Phosphate, 
LipofectamineTM (Invitrogen) or GeneJuiceTM (Merck/Novagen) according to the 
manufacturer's protocol. 
2.2.2.1 Calcium  Phosphate  Transfection  
Cells were seeded at 2-2.5 x 105/ml and allowed to adhere for 24H prior to 
transfection. For a 10cm TC dish, 20 µg of plasmid DNA was aliquoted into a sterile 
1.5 ml microfuge tubes. 2xHBS was added to bring the combined volume to 500µl. 
30µl 2.5M CaCl2 was then added and mixed gently during the addition. After 20min 
incubation, solution was added dropwise to the cells. Cells were incubated at 37°C 
for 24-48 hours before harvesting. For a 6-well plate, 12- well plate or 24-well plate, 
reaction was scaled down appropriately. 
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2.2.2.2 Genejuice  Transfection  
GenejuiceTM transfection (Merck/Novagen) was carried out when transfecting cells 
in a 96wp format to increase transfection efficiency with small cell numbers. Cells 
were seeded at 1-1.5 x 105/ml and allowed to adhere for 24H prior to transfection. 
Transfection was carried out as per the manufacturer’s instructions. Genejuice was 
diluted in serum free medium (SFM) at a 1:25 dilution and left for 5min. This was 
added to DNA previously prepared in a (96well v-bottomed plate, the 
DNA/Genejuice mixture was left for 15 min before addition to the cells in a 96 well 
plate. A total amount of 230ng DNA in 10µl GeneJuice/SFM mixture was added to 
each well. Cells were incubated at 37°C for 24-48 hours before harvesting. 
2.2.2.3 Lipofectamine/siRNA  Transfection  
Lipofectamine 200 was used in cases where siRNA was to be transfected into cells 
as recommended by the siRNA manufacturer (Invitrogen) instructions. Short 
Interfering RNA (siRNA) can be used to interfere with the expression of specific 
mRNAs containing complementary nucleotide sequences. Cells were seeded at 2-2.5 
x 105/ml and allowed to adhere for 24H prior to transfection.  Lipofectamine 2000 
was used to transfect HEK293T cells with StealthTM RNAi oligonucleotides 
(Invitrogen) specific for DDX3 (Section 6.1) or a control siRNA with matched GC 
content. For a 6-well plate, 100pmole (5µl) of siDDX3 or si medium GC was added 
to 125µl of Optimem (Gibco) in a sterile eppendorf tube. 125µl of Optimem (Gibco) 
was mixed with 5µl Lipofectamine 2000 in a sterile eppendorf, and left for 15 min. 
The Lipofectamine/Optimem mix was added to the siRNA/Optimem eppendorf tube 
mixed with pipetting, and incubated for 15 min. 255µl of Lipofectamine/siRNA mix 
was added to cells. After 24 h, cells from each well were split into two new wells. 
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The following morning a second siRNA transfection was carried out, and 6 h later 
expression plasmids were transfected into cells using the calcium phosphate method 
as section 2.2.2.1. In the case of an experiment in a 96wp formant cell were 
harvested from the 6 well plate (wp) and transferred to a 96wp and left for 24H, cells 
were then transfected with genjuice as described in section 2.2.2.2. Knock-down was 
confirmed by Western blotting. 
2.2.3 shRNA  Cells  
For some experimental conditions inducible DDX3 knockdown cells were used. 
These cells were produced by Dr. Yvette Hoehn (Host-Pathogen Interaction Lab, 
NUI Maynooth) using a TRIPZ inducible lentiviral shRNA system. HEK293 cells 
were transfected using lentivirus with a pTRIPZ vector that inducibly expressed 
shRNA targeted against either DDX3 or a Non-Silencing control shRNA. Cells were 
maintained in the presence of 10µg/ml puromycin to select for stable cells. 
Knockdown was induced by addition of 0.5µg/ml doxycycline when cells were being 
plated. Knockdown was assessed by western blotting. 
2.2.4 Cell  treatments  
For Sendai virus (SeV, Charles River Laboratories) stimulation, Sendai virus was 
added at a 1:200 dilution from original stock (16,000/ml) at required time points. 
CLO75 was used at a final concentration of 1µg/ml of medium for the required time. 
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2.3 Luciferase  Reporter  Gene  Assay  
Cells were plated in flat bottomed 96wp and transfected with 80 ng of plasmid 
vectors containing a firefly luciferase gene under the control of the promoter region 
from either ifnα4 or ifnβ gene as in section 2.2.2.2. In addition a control construct 
containing 20 ng of a renilla luciferase gene that is constitutively expressed was also 
transfected to allow normalisation of the data to take into account of transfection 
efficiency among other factors. Other constructs relevant to the experimental 
condition were also transfected, however, the total DNA concentration transfected 
into each well was brought to 230 ng with the appropriate empty vector. If cells were 
to be stimulated they were left for 24h at 37oC at 5% Co2 and the treatment was 
applied for the appropriate time. 24 h after the transfection (or in the case of 
stimulation the appropriate time after stimulation), the medium was removed from 
the wells. 50 µl of 1X Reporter Lysis Buffer (from 5X Reporter Lysis Buffer diluted 
in water, Promega) was added to each well. The plate was then placed on a rocker at 
room temperature for 15 min and frozen. The cell lysates were then thawed at room 
temperature on a rocker. 20 µl of each lysate was pipetted into two separate white- 
bottom 96-wells plates. Firefly luciferase activity was assessed by adding 40 µl of 
firefly luciferase substrate to one white 96wp, whilst renilla luciferase activity was 
assayed diluting 0.1 µg/ml Coelenterazine in PBS straight before use (Promega). The 
luminescence was then measured in a luminometer. All experiments were carried out 
in triplicate. 
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2.4 Co-­‐Immunoprecipitations  
Protein G Sepharose Beads (Sigma), were prepared 24h in advance of cell lysis by 
incubating 20 µl of bead suspension per IP with 5% BSA in PBS-.1%Tween with an 
antibody for the protein to be immunoprecipitated, overnight at 4oC with constant 
rotation. 
Lysates for co-immunoprecipitation (co-ip) experiments were prepared by washing 
cells once with ice-cold 1X PBS and adding lysis buffer to each well. In all steps 
following addition of lysis buffer care was kept to keep samples on ice at all times. 
Lysates were transferred to pre cooled 1.5ml tubes and incubated for 45 mins on a 
rocker in ice. Lysates were then centrifuged at 13000g for 15 minutes. The 
supernatants were transferred into new 1.5 ml tubes. An aliquot of the lysates was 
added to the appropriate amount of 2X lamelli sample buffer and boiled for 5 mins. 
The rest of the lysate was used for the co-ip. The pre-prepared beads were washed 
twice with cold PBS and once with lysis buffer and aliquoted evenly into precooled 
1.5ml tubes. Cell lystes were added to the beads and tubed were incubated overnight 
at 4oC with constant rotation. Beads were washed three times with 1ml of cold lysis 
buffer and then then resuspended in 2x laemmli sample buffer and boiled for 10min 
at 100oC. Co-immunoprecipitation samples were then subjected to SDS-PAGE and 
Western blotting (Section 2.5, 2.5.2). 
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2.5 SDS-­‐PAGE  and  Western  Blotting  
2.5.1 SDS-­‐PAGE  
Samples to be subjected to SDS-page were prepared as in section 2.4 with cell 
lysates/protein samples being mixed with 2x lamelli sample buffer with subsequent 
boiling for 10mins. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was 
conducted in a Biorad Mini-Protean® Tetra System. The prepared samples were 
loaded into the wells of a pre-prepared gel (typically a 5% poly acrylamide stacking 
gel and a 10% resolving gel) along with a protein molecular weight marker 
(Fermentas). Gels were then run in SDS- PAGE running buffer at 100-150 V 
constant voltage for 50-90 minutes, or until sufficiently resolved. (All buffers and 
gel composition is outlined in appendix) 
2.5.2 Western  Blotting  
Once the proteins had been separated by SDS-PAGE, they were transferred 
electrophoretically to a polyvinylidene fluoride (PVDF) transfer membrane 
(Millipore) in a semi-dry electrophoretic transfer unit (Biometra) at 90mA/gel. 
Membrane was pre-soaked in methanol (Sigma-Aldrich) and cold transfer buffer for 
10 min. After transfer, the membrane was allowed to dry at room temperature 
overnight while also being protected from light. The membrane was reactivated by 
being place shortly in methanol followed by a quick was in TBS 0.1% Tween. The 
membrane was then incubated in a blocking solution (5% semi-skimmed milk 
powder in TBS/0.01 % Tween (Sigma)) at room temperature for 1h to prevent non-
specific antibody binding. Subsequently, the membrane was incubated with a 
primary antibody, in 5% Milk TBS/Tween, at 4°C overnight. Following 3 x 5min 
washes with TBS/0.1%Tween, the membrane was then incubated with the 
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appropriate horseradish peroxidase conjugated secondary antibody for 1h at room 
temperature, and then washed again 3 x 5 min with TBS/0.1%Tween. 
2.5.3 Chemiluminescence  detection  
Immunoreactive proteins were detected using Enhanced ChemiLuminescence (ECL). 
ECL was prepared and then added to the membrane for 30 secs. Membranes were 
placed between two layers of plastic and placed in a film cassette. In the dark room, 
Autorad film (UltraCruzTM Autoradiography Film, Santa Cruz Biotechnology) was 
placed on top of the membranes in the cassette for 1-30 min. Autorad film was then 
developed and fixed using a Fuji Medical film processor (Fuji). 
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2.6 Blue  Native  Page  
HEK 293T cells were cultured in 10cm dishes and stimulated for the desired time. 
Cells were counted and a set number of cells were used for the experiment. The cell 
pellet was resuspended in cold Blue-Native (BN) -Lysis buffer. The sample was 
incubated on ice for 15 min and centrifuged at 13,000g for 15 min. The lysate was 
dialysed for 6 hours in cold BN-dialysis buffer at 4oC with constant stirring. 
All plates and equipment to be used in running the native gels were soaked in water 
overnight and cleaned thoroughly to ensure no trace of SDS was present. One of the 
most important things to be aware of is the presence of SDS. A lot of care must be 
taken to ensure no SDS is present on any of the equipment or in any of the reagents 
used in the experiment. If SDS gets in the sample it will disrupt any complexes that 
are still present. Best practice is to have a separate area for working with BN-PAGE 
gels in isolation from any areas where SDS is used. 
Blue native gradient gels were poured and left to cool to 4oC before loading the 
dialysed samples. The samples were loaded into dry wells along with a native 
molecular weight marker, empty wells were loaded with some BN-lysis buffer. The 
wells were then overlaid with cold cathode buffer, the inner chamber in the gel rig 
was then gently filled with cold cathode buffer while the outside was filled with the 
cold anode buffer. The gels were run overnight at 25 volts at 4oC until the blue 
running front reached the bottom of the gel. A native marker mix was used to 
estimate the sizes of the complexes in the samples. In our experiments we used a 
range of proteins whose sizes covered the range of complexes that we were 
interested in. BSA (66 and 132kD), Catalase (232kD) and Ferritin (440 and 880kD) 
were used. An advantage of using BSA and Ferritin is that in addition to their 
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monomer form they also exist as dimers providing two size markers for the marker 
mix and possibly providing an indication of SDS contamination, if SDS is present it 
will disrupt the dimer of the marker in addition to the complexes in the samples, an 
additional advantage of ferritin is that it is coloured and can be seen while the gel is 
running providing an indication of how well the gel is progressing. The sizes of the 
detected complexes can vary from the predicted values however due to a number of 
factors for example detergent micelles may form around a membrane complex which 
would add to its observed size (Swamy, Siegers, et al. 2006) therefore the sizes given 
by the marker mix should be taken as a guide only. 
For experiments that only required the first dimension the gel was transferred using 
the usual western blotting procedure. For samples that required a second dimension 
an SDS-Page gel was prepared with one small lane for the molecular weight marker 
and one long lane. The lanes on the blue native gel were cut out and the slices were 
placed into SDS sample buffer for 10 minutes followed by a quick boiling in the 
microwave for no more than 20 seconds. The slice was left in the sample buffer for 
another 10-15mins and it was then loaded into the long lane of the SDS-Page gel, 
overlaid with SDS sample buffer and run according to normal SDS PAGE protocols 
with subsequent western blotting. 
A thorough and in-depth protocol for BN-PAGE with additional troubleshooting 
advice can be found in Swamy, M. et al. and Wittig, I. et al. (Swamy, Siegers, et al. 
2006; Wittig et al. 2006). 
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2.7 Competent  Cell  Preparation  
Chemically competent cells were prepared from E.coli strain Novablue (Merck) 
(endA1) or E.coli strain BL21/DE3 (NEB) with CaCI2 solution, which facilitates 
transformation of the cells with DNA. 50 µl of Novablue competent cells were added 
to 5 ml of LB broth, and cultured overnight at 37°C. LB broth (100ml) was 
inoculated with 1ml of the E.coli overnight pre-culture and incubated at 37°C until 
the OD600 of the culture reached 0.4-0.8 (after approximately 6 hours). Then, the 
bacteria were pelleted by centrifugation at 4°C for 20 minutes at 3,000g. The pellet 
was immediately resuspended in 34ml of ice-cold transformation buffer (TB) and 
incubated on ice for 10 minutes. The cells were pelleted as before and resuspended 
in 8ml ice-cold TB. 600 µl of Dimethyl sulphoxide (DMSO, Sigma-Aldrich) was 
added and the cells were incubated on ice for a further 10 minutes. Aliquots of 200-
300 µl were snap frozen in liquid nitrogen and stored immediately at - 80°C. 
2.7.1 Transformation  of  chemically  competent  cells  
Competent cells were thawed on ice. 50 µl of cells were transferred into a cold 1.5ml 
tube containing 50 ng of plasmid DNA and kept on ice for 10 mins before being 
heat- shocked for 30 seconds at 42°C, and then placed on ice for a further 2 minutes. 
The cells were immediately plated onto LB agar plates (LB broth with 1.5 % (w/v) 
agar) containing 100µg/ml ampicillin antibiotic and incubated at 37°C overnight. 
For kanamycin resistant plasmids an additional outgrowth step was required. After 
heat-shock 100µl of SOC medium or LB broth was added to cells, and the tube was 
left shaking at 37°C in a bacterial incubator for 1h. Outgrowth at 37°C for 1 hour is 
best for cell recovery and maintenance of antibiotic resistance. Transformed cells 
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were then spread onto LB agar plates containing 100µg/ml kanamycin and incubated 
at 37°C overnight. 
2.7.2 Large  scale  DNA  preparation  
Plasmid isolation and purification from bacterial cells was performed using the 
Nucelobond Xtra Midi Kit (Macherey-Nagel) according to the manufacturer's 
protocol. Briefly, a starter culture of LB broth (5ml) containing appropriate antibiotic 
was inoculated with a single transformed E.coli colony and incubated at 37°C with 
constant shaking for 3-6h. This was then added to LB broth (100ml) containing 
appropriate antibiotic and incubated over night at 37°C with constant shaking. The 
bacterial cells were centrifuged at 3000g for 20mins and subjected to lysis and 
purification as per the manufacturer's instructions. All plasmids were eluted in 
molecular grade water. DNA concentrations and purity were determined using a 
NanoDrop® ND-1000 Spectrophotometer according to the manufacturer's protocol. 
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2.8 Protein  Work  
2.8.1   Production  of  recombinant  6His-­‐tagged  and  GST-­‐tagged  proteins  
in  BL21  Ecoli  
1 µl plasmid DNA (pHis-Parallel-2 expression plasmid) was transformed chemically 
into competent E. coli strain BL21/DE3 (New England Biolabs) as section 2.7.1. 
Overnight pre-culture was performed at 37°C by inoculating with one transformed 
colony in 12 ml of LB (AMP) overnight. Alternatively, 5 µl of a glycerol stock was 
used to inoculate the 12ml pre-culture of LB (AMP). 10 ml of the overnight pre-
culture was inoculated into a 100 ml LB (AMP) culture and incubated at 37°C up to 
the logarithmic phase of growth. When OD600 =1.2, protein expression was induced 
by the addition of isopropyl β-D-1 thiogalactopyranoside (IPTG) to a final 
concentration of 100 µM at room temperature overnight. The E.coli cells were 
pelleted by centrifugation of 4000g for 15min at 4°C, and then resuspended in 1 ml 
native lysis buffer for 6His-tagged proteins (or for GST proteins in GST lysis 
buffer). Lysates were snap frozen in liquid nitrogen and thawed using a water bath. 
Three cycles of freeze-thawing were carried out. Additional sonication (30% power 
for 10sec x 3) were performed on the lysates to completely lyse the bacteria. The 
lysates were cleared by centrifugation at 13000g for 30 min. 100 µl Ni-NTA bead 
slurry (Qiagene) for his proteins (or Glutathione Sepharose (GS) bead slurry (70%, 
1.4 ml, GE Heathcare) for GST proteins) was washed three times with His-Wash 
Buffer (or GST wash buffer), then added to the cleared lysates, and incubated at 4°C 
for overnight with constant rotation. The beads were then washed twice with 1.5 ml 
of the appropriate washing buffer I and II and the proteins were eluted by 100µl of 
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elution buffer. Aliquots of protein were run on SDS-PAGE and stained with 
Coomasie Blue to assess purity and amount of purified recombinant proteins. 
2.8.2 Coomassie  staining  
SDS-PAGE gels were stained with Coomassie Blue Staining Solution for 5 minutes 
on a rocker, followed by destaining in de-stain solution until the background was 
clear. 
2.8.3 In  vitro  pulldown  assay  
For pull-downs, equal amounts of the different His- or GST- tagged fusion proteins 
were used, as estimated by SDS–PAGE and Coomassie Blue staining prior to use. 
Cell lysates containing Myc-tagged proteins expressed in HEK293T cells or 0.5µg of 
recombinant protein were incubated with the purified His- or GST-tagged proteins 
coupled to Nickel-Agarose or Glutathione-Sepharose respectively, with constant 
rotation for 4h or overnight at 4°C. Beads were washed three times in 1.5ml lysis 
buffer, and then all the liquid drained. Beads were then resuspended in 2x Laemmli 
sample buffer and boiled for 10min at 95 oC. Sample were analysed for interactions 
by SDS-PAGE and Western blotting. 
2.8.4 Kinase  assay  
Human N-terminal GST- HIS6-tagged IKK-epsilon, Human IKK-beta and human 
NF-kappaB-inducing kinase (NIK), proteins were purchased from ProQinase. 
Recombinant full- length human IKKα, containing an N-terminal GST-tag, was from 
Millipore. 
In all experiments 55ng of recombinant kinase protein in 1 µl was used, to this, a 
master mix of 10 µl of 2X kinase assay buffer with 5 µg of substrate was added. An 
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ATP solution containing [γ-32P] ATP (5 µCi/tube, correspondent to 0.5 µl; Perkin-
Elmer) and 200 µM ATP (2.5 µl/tube; Sigma- Aldrich) was prepared. 3 µl of this 
ATP mix were added to each tube. The tubes were incubated for 30 minutes at 30°C, 
then 3µl 6X sample buffer was added, and the tubes boiled at 95°C for 10 minutes; 
the boiled samples were then run on a 10% polyacrylamide gel. The incorporation of 
[γ- 32P] ATP was then evaluated by autoradiography of the gel (generally, 24h 
exposure). Non-radioactive kinases assay were also carried out where the addition of 
[γ-32P] ATP was omitted, visualisation of these result was obtained by carrying out 
western blotting on the gel followed by probing with appropriate antibodies.  
GST-IRF7 (aa 468-503) peptides and constructs were kindly provided by Prof John 
Hiscott and Dr Qiang Sun (McGill University, Montreal). 
2.9   Statistical  analysis.  
Data analysis was carried out using the unpaired Student t test using Microsoft 
Excel. Every experiment has been conducted at least three times, each time in 
triplicate, unless otherwise stated. Statistically significant differences are indicated 
by the asterisks: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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2.10 Antibodies  
Antibody Company Species Western Dilution 
α-Ha Cambridge Biosciences Mouse 1:1000 
α-Myc Sigma Mouse 1:1000 
α-DDX3 Santa Cruz Mouse 1:200 
α-DDX3 Bethyl Laboratories Rabbit 1:1000 
α-polyHistidine HRP Sigma Mouse 1:1000 
α-Tubulin Abcam Mouse 1:1000 
α-GST HRP  GE Healthcare Goat 1:2000 
α-Flag Sigma Mouse 1:1000 
α-IRF-7 Santa Cruz Mouse 1:200 
α-p52/p100 Millipore Mouse 1:1000 
α-IKKα/β P ser176/180 Cell Signalling Rabbit 1:1000 
α-NIK Cell Signalling Rabbit 1:1000 
α-IKKα Cell Signalling Rabbit 1:1000 
α-IRF7 P ser471/472 Cell Signalling Rabbit 1:1000 
α-p65 P ser468 Cell Signalling Rabbit 1:1000 
α-p100 P ser866/870 Cell Signalling Rabbit 1:1000 
α-IKKα/β ser176/180 II Cell Signalling Rabbit 1:1000 
α-p65 ser536 Cell Signalling Rabbit 1:1000 
Control antibodies for Co-IPs 
Rabbit IgG  Bethyl Laboratories Rabbit  
Mouse IgG2a R&D Systems Mouse  
Secondary antibodies 
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Mouse Fab Sigma  1:3000 
Rabbit Sigma  1:3000 
 
2.11 Recipies  
2.11.1 Lysis  Buffers  
Phospho-Lysis Buffer 
Reagent Final Conc. Stock For 6ml 
NaCl 150mM  1M 909.1 µl  
Sodium Phos-Mono  
Ph 7.5 
0.01M 1M 60 µl  
IGEPAL 0.5% 100% 30 µl  
NaF 50mM 0.5 75 µl  
NaV 1mM 100mM 60 µl 
DTT 1mM 100mM 60 µl 
PMSF 1mM 100mM 60 µl 
EDTA 2mM 500mM 24 µl 
EGTA 1mM 100mM 60 µl 
BGP 1M 100mM 60 µl 
Aprotinin   60 µl  
N-ethylmalemide 2mM 50 mg/ml 31.3 µl 
Water   4612.6 µl  
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RIPA Lysis Buffer 50mM	  Tris-­‐HCL	  pH	  7.4	  
 150mM	  NaCl	  
 1mM	  EDTA	  
 1%	  Triton-­‐X	  100	  
 .5%	  Sodium	  Deoxycholate	  
 .1%	  SDS	  
Protease and phosphatase inhibitors Aprotinin	  (20μl/ml) 
 1	  mM	  sodium	  orthovanadate	  (10μl/ml)	   
 1	  mM	  PMSF	  (10μl/ml) 
IP Lysis Buffer 50mM	  HEPES	  pH	  7.5	  (or	  Tris/HCl	  pH	  7.5)	   
 1mM	  EDTA 
 10%	  Glycerol 
 0.5%	  NP-­‐40	  (or	  1%	  NP-­‐40) 
 150mM	  NaCl 
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2.11.2 General  Reagents  
Resolving Gel Buffer  90.75g Tris 
(1.5M Tris,pH8.8) Add 400ml 
 dH20 Adjust pH 8.8 with HCl 
 Make up to 500ml 
Stacking Gel buffer 15g Tris 
(0.5M Tris,pH6.8) Add 150ml dH20 
 Adjust to pH 6.8 with HCl 
 Make up to 250ml 
10% Resolving Gel  4.1ml dH20 
(2 gels) 3.3ml 30% acrylamide 
 2.5ml 1.5Tris (pH 8.8) 
 100 µl 10% SDS 
 50µl APS 
 Temed 5 µl 
5% Stacking Gel  3.4ml dH20 
(2 gels) 1ml 30% acrylamide 
 1.5ml 1.5Tris (pH 8.8) 
 60 µl 10% SDS 
 60µl APS 
 Temed 6 µl 
 
10x Running buffer 30.3g Trizma Base 
 144g Glycine 
 10g SDS 
 Make up to1L with dH20 
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10x Transfer Buffer 30.3 Tris 
 144g Glycine 
 Make up to 1L with dH20 
1x Transfer Buffer 50ml 10X Transfer Bufer 
 75ml Methanol (15%) 
 Make up to 500ml with dH20 
 
20x TBS pH 7.4 Tris 0.5M (48.4g) 
 NaCl 1.5M (160g) 
 To 1L with dH2O 
 
ECL development solution 24ml of 100mM Tris-HCL pH 8.5 
 7.6 µl of 30% H2O2 
 120 µl of 250mM luminol 
 53.2 µl of 90mM p-Coumaric acid 
 
Transformation Buffer 55 mM MnCl2·4H2O   
 15 mM CaCl2·2H2O   
 250 mM KCl  
 10 mM PIPES (0.5M, pH 6.7)  
 Chilled to 0ºC before use. 
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2X Kinase Assay buffer 40 mM HEPES pH 7.4 
 40 mM MgCl2 
 4 mM DTT 
 40 mM β-glycerophosphate 0.2mM 
Na3VO4 
 1 mM PMSF 
 Complete Mini EDTA-free tablets, 1 
tablet in 10ml 
 0 mM HEPES pH 7.4 
 
Firefly luciferase substrate 470 mM Luciferine (Biosynth) 
 20 mM Tricine 
 2.67 mM Magnesium sulphate 
 0.1 mM EDTA (Promega) 
 2.0 mM DTT (Fisher) 
 5.0 mM ATP 
 270 µM Acetyl-CoA 
 1.07 mM Magnesium carbonate 
 
2X HBS 42 mM HEPES 
 10 mM KCl 
 12 mM dextrose 
 1.5 mM Na2HPO4 · 7H2O 280 mM NaCl 
 42 mM HEPES 
2.5M CaCL2: 36.75g CaCL2.2H20 to 100ml with dH2O 
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10x PBS 85g NaCl 
 4.68g NaH2PO4 
 32.2g Na2HPO4 
 To 1L with dH2O 
PBS/Tween (PBST) 1xPBS 
 0.01% Tween 
 
2x Laemmli sample buffer 2ml 0.5M Tris/Cl pH 6.8 
 2% SDS (use 10% stock) 
 10ml Glycerol 
 200µl bromophenol blue (1% stock in 
ethanol)  
 2ml 1M DTT 
 Make up to 20ml with dH20 
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2.11.3 Reagents  for  protein  work  
Coomassie Blue staining solution 0.25% (w/v) Coomassie Brilliant Blue 
 10% (v/v) glacial acetic acid 
 50% (v/v) methanol 
De-stain solution 25% (v/v) methanol 
 2.5% (v/v) glacial acetic acid 
 
GST lysis Buffer 
pH 8.0 
Reagent Volume Final 
Concentration 
 20x TBS 25ml 1x 
 NaCl 4.38g 150mM 
 1M MgCl2 2.5ml 5mM 
 Sucrose  250mM 
 Glycerol 50ml 10% 
 Triton-X 100 5ml 1% 
 Imidazole 1M 5ml 10mM 
 Β-mercaptoethanol 1.4 µl /ml 20mM 
 To 500ml with dH2O, mercaptoethanol and protease inhibitors 
added just before use. 
GST Wash Buffer 1 Lysis Buffer 1x 
  Imidazole 1M 20mM 
GST Wash Buffer 2 Lysis Buffer 1x 
  Imidazole 1M 40mM 
Elution Buffer Imidazole 1M 250mM 
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His lysis Buffer 
pH 8.0 
Reagent Volume Final 
Concentration 
 NaH2PO4 3g 50mM 
 NaCl 4.38g 150mM 
 Imidazole 1M 5ml 10mM 
 Β-mercaptoethanol 1.4 µl /ml 20mM 
 To 500ml with dH2O, mercaptoethanol and protease inhibitors 
added just before use. 
His Wash Buffer 1 Lysis Buffer 1x 
  Imidazole 1M 20mM 
His Wash Buffer 2 Lysis Buffer 1x 
  Imidazole 1M 40mM 
Elution Buffer Imidazole 1M 250mM 
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2.11.4 Reagents  for  Blue-­‐Native  PAGE  
BN Native marker mix BSA (66 / 132 kDa) 10mg/ml 
 Catalase (232 kDa) 10mg/ml 
 Ferritin (440 / 880 kDa) 10mg/ml 
 Bis Tris 20mM 
 NaCl 20mM 
 Glycerol 10% 
 Adjust pH to 7.0 with HCL 
 
BN Base Buffer  Bis-Tris 20mM 
pH 7.0 (HCL) Ε-Aminocaproic acid 500mM 
 NaCl 20mM 
 EDTA pH 8.0 2mM 
 Glycerol 10% 
For BN Lysis buffer add: Triton-X 100 0.1% 
 Na3VO4 0.5mM 
 IAA 2.5mM 
 PMSF 1mM 
 NaF 0.5mM 
 Protease inhibitor 
cocktail tablet 
1 
BN Dialysis Buffer pH 7.0 BN base buffer  
 Triton-X 100 0.1% 
 PMSF 1mM 
 NaV 0.5mM 
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3xBN-Gel Buffer Bis-Tris 150mM 
 Ε-Aminocaproic acid 200mM 
 Adjust pH to 7.0 with HCL 
BN 3.2% upper gel  3x BN Gel Buffer 2ml 
(4 gels) Acrylamide-
Bisacrylamide mix 32:1 
40% acrylamide 
0.48ml 
 dH2O 3.52ml 
 10% APS 80 ul 
 TEMED 8 µl 
BN 4-12% gradient separating gel (1 gel) 
HIGH 12% 3x BN Gel Buffer 0.833ml 
 Acrylamide-
Bisacrylamide mix 32:1 
40% acrylamide 
0.750ml 
 70% Glycerol 0.917ml 
 10% APS 9.0 ul 
 TEMED 1 µl 
LOW 4% 3x BN Gel Buffer 0.833ml 
 Acrylamide-
Bisacrylamide mix 32:1 
40% acrylamide 
0.250ml 
 dH2O 1.417ml 
 10% APS 9.0 ul 
 TEMED 1 µl 
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BN Cathode Buffer Bis-Tris 15mM 
 Tricine 50mM 
 Coomassie Blue G250 0.02% 
 Prepare a 10x stock, pH to 7.0 with HCL before 
adding coomassie. 
BN Anode Buffer Bis-Tris 50mM 
 Prepare a 10x stock, pH to 7.0 with HCL before 
adding coomassie. 
 
  
90 
 
2.11.5 SDS  PAGE  Gels  
dH2O 
(ml) 
30% 
Acrylamide 
(ml) 
Gel 
Buffer* 
(ml) 
10% w/v 
SDS (ml) 
10% 
APS (µl) 
TEMED 
(µl) 
3.4 1 1.5 .060 30 3 
Table 3: Composition of Stacking SDS-PAGE gel. *0.5M Tris-HCL pH 6.8 
 
% Gel dH2O 
(ml) 
30% 
Acrylamide 
(ml) 
Gel 
Buffer* 
(ml) 
10% w/v 
SDS (ml) 
10% 
APS (µl) 
TEMED 
(µl) 
7% 5.1 2.3 2.5 0.1 30 3 
8% 4.7 2.7 2.5 0.1 30 3 
9% 4.4 3.0 2.5 0.1 30 3 
10% 4.1 3.3 2.5 0.1 30 3 
11% 3.7 3.7 2.5 0.1 30 3 
12% 3.4 4.0 2.5 0.1 30 3 
13% 3.1 4.3 2.5 0.1 30 3 
Table 4: Composition of Resolving SDS-PAGE GEL. *1.5M Tris-HCL pH 8.8 
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3 Results  
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3.1 DDX3   interacts   directly   with   IKKα   and   enhances   its  
activation  
Initially, we sought to determine whether there was an interaction between DDX3 
and IKKα. To this end, we carried out immunoprecipitation assays by co-expressing 
Myc-tagged DDX3 and Flag-tagged IKKα in HEK293T cells and using an anti-Flag 
antibody to immunoprecipitate IKKα. DDX3 showed a strong co-
immunoprecipitation with IKKα in this case (Figure 7). 
 
Figure 7: DDX3 co-immunoprecipitates with IKKα.  
HEK293T cells were transfected with constructs for Flag-IKKα and/or Myc-DDX3. 
Cell lysates were subjected to immunoprecipitation (IP) with an anti-Flag antibody, 
followed by SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments). 
 
 
This co-immunoprecipitation also showed a higher molecular weight form of DDX3 
when both DDX3 and IKKα were expressed together, which is likely to be a 
phosphorylated form of DDX3. As NIK is a related kinase to IKKα and is known to 
work with IKKα in the signalling pathways we are interested in, we also carried out 
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similar co-immunoprecipitations with Myc-tagged DDX3 and Flag-tagged NIK. NIK 
also clearly immunoprecipitated with DDX3 (Figure 8). In this experiment, 
endogenous IKKα also showed strong co-immunoprecipitation with the NIK-DDX3 
complex, suggesting that all three proteins might be in one complex together (Figure 
8, bottom panel). 
 
 
Figure 8: DDX3 co-immunoprecipitates with NIK.  
HEK293T cells were transfected with constructs for Flag-NIK and/or Myc-DDX3. 
Cell lysates were subjected to immunoprecipitation (IP) with an anti-Flag antibody, 
followed by SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
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With this experimental setup it was therefore not clear whether DDX3 interacted 
directly with both IKKα and NIK, as it is possible that IKKα might bridge the 
interaction between NIK and DDX3, and that the observed interaction with NIK was 
therefore indirect. To investigate this further, we carried out pulldown assays using 
recombinant proteins which allowed us to detect direct interactions. Using 
recombinant His-tagged DDX3 purified from E-coli and GST-tagged IKKα in this 
assay, we confirmed a direct interaction between the two proteins (Figure 9). 
 
 
Figure 9: DDX3 directly interacts with IKKα. 
Purified recombinant full-length His-DDX3 was incubated with recombinant GST-
IKKα. Following pulldown with nickel agarose (Ni-Ag), interacting proteins were 
subjected to SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments). 
 
 
As we had confirmed a direct interaction between DDX3 and IKKα, we next sought 
to characterise this interaction further. To this end we used a series of DDX3 
truncation mutants to map the interaction sites between DDX3 and IKKα. Co-
immunoprecipitations were carried out using Flag-tagged IKKα and Ha-tagged 
DDX3 mutants consisting of DDX3 full length (aa 1-662), DDX3 (aa 1-408), and 
DDX3 (aa 409-662). DDX3 (aa 1-408) and DDX3 (aa 409-662) represent the two 
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‘halves’ of DDX3, with the DDX3 protein split at the flexible linker region between 
the two RecA-like globular domains. IKKα successfully co-immunoprecipitated with 
full length DDX3 and with its N-Terminal region (aa 1-408) but not with the C-
terminal region (aa 409-662) (Figure 10). 
	  
	  
 
Figure 10: IKKα interacts with the N-terminal region of DDX3.  
HEK293T cells were transfected with constructs for Flag-IKKα and one of Ha-
tagged DDX3 full length (aa 1-662), DDX3 (aa 1-408), or DDX3 (aa 409-662). Cell 
lysates were subjected to immunoprecipitation (IP) with an anti-Flag antibody, 
followed by SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
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In addition, pulldown assays, carried out by Dr. Lili Gu in our Host-Pathogen 
Interaction Lab, using recombinant His-tagged DDX3 mutants (DDX3 (aa 1-408), 
DDX3 (aa 139-408), DDX3 (aa 172-408) and DDX3 (aa 409-662)), to pull down 
flag-IKKα from cell lysates, corroborated these findings and further narrowed the 
binding site for IKKα on DDX3 (Figure 11). In this experiment IKKα interacted 
with the 1-408 and the 139-408 aa regions of DDX3, but not with the 172-408 and 
409-662 aa regions (Figure 11). This suggested that IKKα interacts somewhere 
between aa 139 and aa 172 of DDX3, although it does not exclude the possibility of 
additional binding sites within the N-terminus of DDX3. 
 
 
Figure 11: IKKα interacts with the region between aa 139 to 172 of DDX3.  
His-tagged full-length DDX3 (aa 1-408), DDX3 (aa 138-408), DDX3 (aa 172-408), 
or DDX3 (aa 409-662) purified recombinant proteins were incubated with cell 
lysates from Flag-IKKα expressing HEK293T cells. Following pulldown with nickel 
agarose, interacting proteins were subjected to SDS-PAGE and WB analysis with the 
indicated antibodies (Shown is a representative experiment of 3 independent 
experiments). Figure prepared by Lili Gu – host pathogen interaction lab, NUI 
Maynooth. 
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The interaction between IKKα and DDX3 was also detectable at an endogenous 
level. We carried out immunoprecipitations using an endogenous DDX3 antibody or 
a related isotype control antibody, following a time course of CLO75 stimulation in 
HEK293-TLR7 cells. (Figure 12). Endogenous IKKα co-immunoprecipitated with 
DDX3 45 minutes after CLO75 stimulation, which confirmed that DDX3 is involved 
in TLR7/8 signalling via an inducible and transient association with IKKα. 
 
 
Figure 12: Endogenous DDX3 and IKKα interaction induced by the TLR7/8 
ligand CLO75.  
HEK293-TLR7 cells were stimulated for the indicated times with 1µg/ml CLO75. 
Cell lysates were subjected to immunoprecipitation (IP) with an anti-DDX3 antibody 
or the corresponding isotype control antibody, followed by SDS-PAGE and WB 
analysis with the indicated antibodies (Shown is a representative experiment of 3 
independent experiments).  
 
3.1.1 Summary  
In this section we have shown that DDX3 can interact with both IKKα and NIK. We 
have demonstrated that at least IKKα and DDX3 interact directly and that the site of 
interaction/s is in the N-terminus of DDX3. Finally we have also shown that the 
interaction between IKKα and DDX3 can be shown at an endogenous level 
following stimulation with the TLR7/8 ligand CLO75.  
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3.2 DDX3  enhances  IKKα  activation  
Since we have shown a clear interaction between IKKα and DDX3, we next 
endeavoured to investigate what effect, if any, DDX3 has on IKKα activity. In 
previous studies, we have shown that DDX3 enhances IKKε auto-phosphorylation 
and activation (Gu et al. 2013), therefore we hypothesised that DDX3 may perform a 
similar role in the case of IKKα. We carried out both radioactive and non-radioactive 
kinase assays using recombinant DDX3 (aa 1-408), (the region interacting with 
IKKα) and recombinant kinase proteins. Enhanced IKKα auto-phosphorylation was 
observed in samples with DDX3 (aa 1-408) present compared to IKKα alone 
(Figure 13a). In addition, the non-radioactive kinase assays using a phospho-IKKα 
ser176/180 specific antibody confirmed that this enhanced phosphorylation is due at 
least in part to enhanced phosphorylation on the serines 176/180 present in the 
activation loop of IKKα (Figure 13b). 
 
Figure 13: DDX3 enhances IKKα auto-phosphorylation in its activation loop.  
(A) Recombinant GST-IKKα was incubated with recombinant His-DDX3 1-408 
in the presence of [γ-32P]ATP. Samples were then subjected to SDS-PAGE and 
autoradiograph analysis showing incorporation of [γ-32P]ATP.  
(B) Recombinant GST-IKKα was incubated with recombinant His-DDX3 1-408 
in the presence of ATP. Samples were then subjected to SDS-PAGE and WB 
analysis with the indicated antibodies (Shown is a representative experiment of 3 
independent experiments).  
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To confirm this effect was relevant in cells, we overexpressed Flag-tagged IKKα 
along with Ha-tagged DDX3 or with Ha-tagged K7, a vaccinia virus antagonist of 
DDX3 (Schröder et al. 2008). Subsequent probing with the phospho-specific 
(Ser176/180) IKKα antibody, showed that DDX3 enhanced IKKα auto-
phosphorylation compared to IKKα alone, while K7, presumably targeting the 
endogenous DDX3 present in the cells, reduced this (Figure 14). 
 
 
Figure 14: DDX3 enhances IKKα phosphorylation in its activation loop. 
HEK293T cells were transfected with a plasmid vector for Flag-IKKα and either: 
Ha-DDX3, Ha-K7 or an empty vector. 24h after transfection samples were subjected 
to SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
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To confirm a role for endogenous DDX3 in IKKα activation, we used a system n 
which DDX3 knockdown was inducible by the addition of doxycycline to HEK293-
TLR7 cells stably expressing either pTRIPZ shDDX3 or the corresponding non 
silencing control (NSC) vector. This system allowed us to compare IKKα activation 
between cells with normal and reduced levels of DDX3. Following stimulation with 
CLO75 for 24 hours, the non-silencing control cells showed a slight increase in 
IKKα phosphorylation upon stimulation (Figure 15). However, IKKα 
phosphorylation, both in the presence and absence of CLO75 stimulation, was 
severely reduced in cells with reduced DDX3 (Figure 15). 
Experiments using shorter time-points of stimulation showed that CLO75 increased 
IKKα phosphorylation, which peaked at approximately one hour after stimulation 
(Figure 15). In DDX3 knockdown cells both background levels and the induced 
IKKα phosphorylation were reduced. However, some phosphorylation did occur in a 
delayed manner compared to control cells, with some phosphorylation being 
observed at four hours after stimulation (Figure 15). 
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Figure 15: Knockdown of DDX3 both reduces and delays IKKα activation. 
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293-TLR7 cells stably expressing either pTRIPZ shDDX3 or the 
corresponding non-silencing control (NSC). Cells were then stimulated with CLO75 
for the indicated time periods followed by SDS-PAGE and WB analysis with the 
indicated antibodies (Shown is a representative experiment of 3 independent 
experiments) (A, C). Densitometry was carried out on IKKα and P-IKKα bands. 
Shown are P-IKKα band intensities shown as a percentage of total IKKα band 
intensity (B,D). 
  
C 
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3.2.1 Summary  
In this section we have investigated possible effects of the interaction between IKKα 
and DDX3. We have shown that DDX3 can enhance auto-phosphorylation of IKKα 
in its activation loop and that the DDX3 antagonist K7 can reduce this 
phosphorylation. We have also shown that knockdown of endogenous DDX3 can 
reduce and delay the activation-phosphorylation of IKKα following CLO75 
stimulation. Our results clearly show that DDX3 has a direct role in enhancing IKKα 
auto-phosphorylation in its activation loop, therefore we next investigated signalling 
pathways that involve IKKα to determine whether there was any functional 
consequence of this interaction. 
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3.3 The  effects  of  DDX3  on  the  alternative  NF-­‐κB  pathway  
3.3.1 DDX3  enhances  processing  of  p100  
To investigate a possible role of DDX3 in the alternative NF-κB pathway, we first 
set up a read-out system to test the effects on this pathway. A characteristic feature 
of this pathway is the processing of the p100 precursor NF-κB subunit to the smaller 
p52 subunit. The size difference between the two allowed us to visualise p100 
processing simply by western blotting with an antibody that recognises both p100 
and p52, and thus estimate the extent of induction of the pathway. Processing of 
p100 was inducible by a number of immune-relevant stimuli, including TNFα, 
CLO75, and Sendai Virus (SeV) (Figure 16). 
 
 
Figure 16: The alternative NF-κB pathway can be induced by CLO75, SeV and 
TNFα.  
HEK293T cells were stimulated for the indicated time periods with TNFα (A) or 
SeV (B). HEK293-TLR7 cells were stimulated for the indicated times with CLO75 
(C). Cell lysates were then subjected to SDS-PAGE and WB analysis with the 
indicated antibodies (Shown is a representative experiment of 3 independent 
experiments). 
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We showed that in addition to TNFα, p100 processing was inducible by both Sev 
and CLO75 demonstrating that it occurs downstream of RIG-I and TLR7 (Figure 
16). 
Using this setup as a readout for induction of the alternative NF-κB pathway, we 
then investigated the possible role of DDX3. Initially, we overexpressed Ha-tagged 
DDX3 or an empty vector control in HEK293T cells. Western-blot analysis showed 
that in the samples with DDX3, there was an increased smear in the band for p100 
along with increased levels of p52 (Figure 17). A key step in the processing of p100 
is K48-linked ubiquitination, which tags it for processing to p52 by the proteasome 
(Xiao et al. 2004). The smear we observed may well be indicative of this 
ubiquitination. This result was a first indication that DDX3 might play a role in the 
activation of this pathway, and therefore further investigation was warranted.  
 
Figure 17: DDX3 induces a smear in p100 and increases levels of p52.  
HEK293T cells were transfected with a plasmid vector for Ha-DDX3 or an empty 
vector (EV). 24h after transfection cells were subjected to SDS-PAGE and WB 
analysis with the indicated antibodies (Shown is a representative experiment of 3 
independent experiments). 
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To investigate if DDX3 could affect p100 processing, we expressed a low and a high 
amount of Myc-tagged DDX3 or the Ha-tagged DDX3 antagonist K7 and 
subsequently stimulated HEK-293T cells with Sev for 24h. Increasing amounts of 
exogenous DDX3 led to a dose dependent enhancement of SeV-induced p100 
processing, while the DDX3 antagonist K7 seemed to reduce this, demonstrating that 
DDX3 is a positive enhancer of p100 processing (Figure 18).   
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Figure 18: DDX3 enhances p100 processing.  
HEK293T cells in 6 well plates were transfected with a plasmid vector for Ha-K7, 
Myc-DDX3 or an empty vector (++ 4µg plasmid DNA, + 2µg plasmid DNA). 24h 
after transfection cells were stimulated with SeV for 24h, samples were then 
subjected to SDS-PAGE and WB analysis with the indicated antibodies  (Shown is a 
representative experiment of 3 independent experiments). Upper Panel) 
Densitometry was carried out on P52 and Tubulin bands. Shown are P52 band 
intensities normalised using Tubulin band intensities (Lower panel).  
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We next used our inducible DDX3 shRNA knockdown system in HEK293T cells 
and investigated the effect of reduced DDX3 levels on p100 processing induced by 
NIK and IKKα. We induced processing by expressing Flag-tagged NIK and IKKα in 
both control and knockdown cells and observed that p100 phosphorylation on serines 
866/870 was somewhat reduced in cells with lowered DDX3 levels. These two 
serines are required for induction of p100 processing by facilitating the binding of 
IKKα to p100 (Xiao et al. 2004). As expected, this reduction in p100 
phosphorylation corresponded to a matching reduction in p100 processing and 
therefore p52 levels (Figure 19). 
 
Figure 19: DDX3 knockdown reduces NIK-IKKα induced phosphorylation and 
processing of p100.  
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293T cells stably expressing either pTRIPZ shDDX3 or the corresponding 
non-silencing control (NSC). Cells were then transfected with a plasmid vector for 
Flag-IKKα and Flag-NIK or an empty vector. 24h after transfection cells were then 
subjected to SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
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In a similar experiment, using inducible DDX3 knockdown in HEK293-TLR7 cells, 
p100 phosphorylation was also reduced following CLO75 stimulation in DDX3 
knockdown cells compared to control cells (Figure 20). In the same experiment 
IKKα phosphorylation was also delayed which could explain the reduced 
phosphorylation of p100. In addition, p100 processing to p52 was somewhat reduced 
in DDX3 knockdown cells. 
 
 
Figure 20: Knockdown of DDX3 reduces CLO75 induced p100 
phosphorylation.  
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293-TLR7 cells stably expressing either pTRIPZ shDDX3 or the 
corresponding non-silencing control (NSC). Cells were then stimulated with CLO75 
for the indicated time periods and subjected to SDS-PAGE and WB analysis with the 
indicated antibodies (Shown is a representative experiment of 3 independent 
experiments).  
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3.3.2 DDX3  interacts  with  NF-­‐κB  subunits  
With DDX3 and IKKα being in complex with each other, we next questioned 
whether downstream proteins could also form a complex with DDX3. In the case of 
the alternative NF-κB pathway we carried out co-immunoprecipitations with Myc-
Tagged DDX3 and Ha-tagged p52 or p65. DDX3 clearly co-immunoprecipitated 
with both of these NF-κB subunits in this setup (Figure 21). 
 
 
Figure 21: DDX3 interacts with p52 and p65. 
HEK293T cells were transfected with constructs for Ha-P52 of Ha-p65and/or Myc-
DDX3. Cell lysates were subjected to immunoprecipitation (IP) with an anti-Ha 
antibody, followed by SDS-PAGE and WB analysis with the indicated antibodies 
(Shown is a representative experiment of 3 independent experiments).  
 
 
While p52 is a typical component of the alternative NF-κB pathway, p65 is a 
component of the classical NF-κB pathway. It can however be involved in the 
“hybrid pathway”, in which p52 can dimerise with a subunit of the classical NF-κB 
pathway like p65 (Wietek et al. 2006). We next carried out endogenous co-
immunoprecipitations of DDX3. DDX3 interacted with endogenous p100 and p65 
constitutively (Figure 22). However, while stimulation of cells with CLO75 did not 
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affect the interaction with p100, the interaction with p65 was lost and only 
reappeared at the 24h time-point (Figure 22). Unfortunately we were unable to 
visualise p52 in these experiments as the size of p52 and the heavy chain of the IP 
antibody are a very similar size. With the IP and WB probing antibodies both 
produced in mouse the heavy chain of the IP antibody was bound by the mouse 
secondary antibody and obscured any p52 bands. 
 
 
 
Figure 22: DDX3 constitutively interacts with p100 and p65.  
HEK293-TLR7 cells were stimulated for the indicated time periods with 1µg/ml 
CLO75. Cell lysates were subjected to immunoprecipitation (IP) with an anti-DDX3 
antibody or the corresponding isotype control antibody, followed by SDS-PAGE and 
WB analysis with the indicated antibodies (Shown is a representative experiment of 
3 independent experiments). 
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3.3.3 Summary  
In this section we investigated effects of DDX3 on one of the pathways that IKKα is 
involved in – the alternative NF-κB pathway. We showed that this pathway is 
activated following TLR7 and RIG-I stimulation. We have shown that in addition to 
DDX3 enhancing p100 processing its antagonist K7 can also inhibit this effect. We 
have demonstrated that knockdown of endogenous DDX3 reduces both 
phosphorylation of p100 at Ser866/870 and p100 processing downstream of NIK and 
IKKα, and following CLO75 stimulation. In an effort to investigate the role of 
DDX3 in this pathway further, we have also shown that DDX3 interacts with a 
number of NF-κB subunits, namely p52, p100, and p65. 
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3.4 Effects  of  DDX3  on  TLR7  signalling  
3.4.1 DDX3  is  involved  in  IFN  induction  downstream  of  TLR7  
While investigating the alternative NF-κB pathway, one of the ligands we used was 
CLO75, which stimulates TLR7/8. The TLR7 pathway is more commonly associated 
with the induction of large amounts of type 1 IFN following receptor engagement. 
As the pathway to IFN induction is in this case also mediated by NIK and IKKα, we 
considered a possible role of DDX3 in this pathway. Initial investigations were 
carried out by performing luciferase reporter gene assays, measuring induction of 
type 1 IFN promoters. Activation of the ifnb and ifna4 promoters was induced by 
overexpressing both NIK and IKKα; and the involvement of DDX3 was assessed by 
co-expressing DDX3, its antagonist K7 or a dominant negative form of DDX3 (aa 1-
139) (Schröder et al. 2008). Although a role for DDX3 in IFNβ induction had been 
shown previously, this was in the context of pathways mediated by the kinases 
IKKε/TBK1 (Schröder et al. 2008; Soulat et al. 2008). We demonstrated that our 
experimental setup was independent of these two kinases by using dominant 
negative forms of IKKε and TBK1 or the IKKε/TBK1 inhibitor BX795. Neither co-
expression of the two dominant negative constructs nor the IKKε/TBK1 inhibitor 
had any effect on ifnb or ifna4 promoter induction by NIK and IKKα (Figure 23 
A+B). However DDX3 enhanced, while K7 and the dominant negative DDX3 (aa 1-
139) inhibited both ifnb and ifna4 induction (Figure 23 A+B). 
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Figure 23: DDX3 mediates induction of IFNα4 and IFNβ by NIK/IKKα.  
HEK293 cells were transfected with an ifnα4 (A) or ifnb (B) promoter reporter gene 
construct and expression constructs for Flag-IKKα/Flag-NIK and HA-DDX3, Ha-
K7, HA-DDX3 1-139 or the dominant negative of TBK1/IKKε. Where indicated the 
inhibitor BX795 (50 ng/ml) was added 24h later and left for an additional 24h. Data 
for reporter gene assays are expressed as mean fold induction relative to control 
levels, +/- standard deviations. Shown are results of one representative experiment 
out of four, performed in triplicate. 
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In addition to inducing the pathway by overexpressing NIK and IKKα, we also 
carried out similar assays using CLO75. As HEK293-TLR7 cells naturally possess 
very low levels of the transcription factor IRF7, which is needed to activate the 
IFNα4 promoter, we co-transfected a small amount of IRF7. Transfection of a DDX3 
construct resulted in a dose dependent increase in the induction of both ifnb and 
ifna4 promoters (Figure 24). 
 
Figure 24: DDX3 enhances IFNα4 and IFNβ induction following CLO75 
stimulation.  
HEK293-TLR7 cells were transfected with an ifnα4 (A) or ifnb (B) promoter 
reporter gene construct and expression constructs for HA-DDX3 and Flag-IRF7. 24h 
after transfection cells were stimulated for the indicated times with 5µg/ml CLO75 
for an additional 24h. Data for reporter gene assays are expressed as mean fold 
induction relative to control levels +/- standard deviations. Shown are results of one 
representative experiment out of four, performed in triplicate. 
  
116 
 
Similar luciferase reporter gene assays were carried out using DDX3 knockdown 
cells, both using the inducible shRNA system mentioned previously, and also by 
using unrelated siRNA oligos targeting DDX3. While these experiments did not 
result in statistically significant results, there did appear to be a trend of reduced 
induction in cells with decreased DDX3 levels (Figure 25). 
 
Figure 25: Knockdown of DDX3 may decrease induction of IFNα4 and IFNβ.  
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293T cells stably expressing either pTRIPZ shDDX3 or the corresponding 
non-silencing control (NSC) (A,B) or by using an established siRNA oligo (Gu et al. 
2013; Schröder et al. 2008) (C,D). The cells were then transfected with an ifna4 or 
ifnb promoter reporter gene construct and expression constructs for Flag-IKKα/NIK. 
24h after transfection cells were harvested and measured. Data for reporter gene 
assays are expressed as mean fold induction relative to control levels with a 
representative experiment from 5 (A,B) or 3 (C,D) independent experiments shown, 
with each experiment performed in triplicate. 
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3.4.2 DDX3  enhances  IRF7  activation  
An important transcription factor for IFNβ induction and an essential one in the case 
of IFNα4 induction is IRF7. Therefore the effects that DDX3 has on IFNα4 (and 
IFNβ) induction are possibly mediated by this key transcription factor. As we have 
previously shown effects of DDX3 on IRF3 (Gu et al. 2013), we therefore 
investigated whether DDX3 can affect the activation of IRF7.  
We first carried out radioactive kinase assays using GST-IKKα, GST-IRF7 (aa 468-
503) and His-DDX3 recombinant proteins. With no other proteins present except 
IKKα and IRF7, the addition of DDX3 enhanced IKKα mediated phosphorylation of 
IRF7 (Figure 26). 
 
 
Figure 26: DDX3 enhances phosphorylation of IRF7 by IKKα.  
Recombinant His-DDX3 and/or recombinant His-IRF7 (aa 468-503) were incubated 
with GST-IKKα and [γ-32P]ATP as indicated. Samples were then subjected to SDS-
PAGE and autoradiograph analysis, showing incorporation of [γ-32P]ATP (Shown is 
a representative experiment of 3 independent experiments).   
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We then continued our investigations in HEK293T cells using an IRF7 antibody 
specific for phosphorylated serine 471/472 residues, which have been linked with 
IRF7 activation (Marié et al. 1998; Ning et al. 2003). We induced IRF7 activation by 
over-expressing small amounts of NIK and IKKα and determined the effect of 
DDX3 by co-expressing DDX3 or its viral antagonist K7. DDX3 enhanced 
phosphorylation of IRF7 on serines 471/472 (Figure 27), while K7 inhibited this 
phosphorylation (not shown)  
 
Figure 27: DDX3 enhances IRF7 Ser471/472 phosphorylation induced by 
NIK/IKKα. 
HEK293T cells were transfected with a plasmid vector for Flag-IKKα and Flag-NIK 
or an empty vector along with Ha-tagged DDX3 or K7. 24h after transfection, cell 
lysates were subjected to SDS-PAGE and WB analysis with the indicated antibodies 
(Shown is a representative experiment of 3 independent experiments). 
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Using our inducible DDX3 knockdown system in HEK293-TLR7 cells, induction of 
IRF7 activation by NIK and IKKα was reduced in HEK293T cells with reduced 
DDX3 levels compared to the corresponding control cells (Figure 28). 
 
 
Figure 28: DDX3 knockdown reduces IRF7 phosphorylation induced by 
NIK/IKKα. 
 DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293T cells stably expressing either pTRIPZ shDDX3 or the corresponding 
non silencing control (NSC). Cells were then transfected with Flag-IRF7 and one of 
the indicated Flag-tagged kinases or an empty vector control. 24h after transfection 
cell lysates were subjected to SDS-PAGE and WB analysis with the indicated 
antibodies (Shown is a representative experiment of 3 independent experiments). 
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Next, we induced IRF7 activation by stimulating HEK293-TLR7 cells with CLO75 
in the DDX3 knockdown system. A time course of stimulation was carried out in 
both control and DDX3 knockdown cells. Cells with reduced DDX3 levels 
demonstrated markedly less IRF7 phosphorylation compared to control cells (Figure 
29). Even though there does not appear to be much increase in phosphorylation upon 
stimulation in the control cells, there does appear to be less overall IRF7 
phosphorylation in DDX3 knockdown cells even at background levels. 
 
Figure 29: Knockdown of DDX3 reduces IRF7 phosphorylation induced by 
CLO75. 
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293-TLR7 cells stably expressing either pTRIPZ shDDX3 or the 
corresponding non-silencing control (NSC). Cells were then transfected with Flag-
IRF7 and 24h later were stimulated with CLO75 for the indicated time periods and 
cell lysates were subjected to SDS-PAGE and WB analysis with the indicated 
antibodies (Shown is a representative experiment of 3 independent experiments). 
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With DDX3 affecting IRF7 activation, we next investigated whether DDX3 was in 
complex with IRF7 in cells. We carried out immunoprecipitation assays by co-
overexpressing Myc-tagged DDX3 and flag-tagged IRF7 in HEK-293T cells and 
using an anti-Flag antibody to immunoprecipitate IRF7. DDX3 showed a clear co-
immunoprecipitation with IRF7 (Figure 30). 
 
Figure 30: DDX3 co-immunoprecipitates with IRF7.  
HEK293T cells were transfected with constructs for Ha-DDX3 and/or Flag-IRF7. 
Cell lysates were subjected to immunoprecipitation (IP) with an anti-Flag antibody, 
followed by SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
3.4.3 Summary  
In this section we have investigated a second pathway that IKKα is involved in – the 
TLR7 pathway to type 1 IFN induction. We have shown that overexpression of 
DDX3 can enhance IFNα4 and IFNβ induction downstream of NIK/IKKα and 
following CLO75 stimulation. In addition, knockdown of endogenous DDX3 
showed a trend of reduced IFN induction. Investigating the role of DDX3 in this 
pathway further revealed that DDX3 enhances the phosphorylation and activation of 
IRF7, with overexpression enhancing and knockdown of DDX3 reducing the 
phosphorylation. Finally we have shown that DDX3 can interact with IRF7.  
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3.5 DDX3  enhances  the  IKKα  interaction  with  NIK  and  IRF7  
So far, we have shown that DDX3 can enhance auto-phosphorylation and activity of 
IKKα and that this resulted in increased induction of the pathways IKKα is involved 
in. We next investigated in more detail how DDX3 exerted this effect on IKKα. We 
examined whether protein interactions with IKKα were affected. Co-
immunoprecipitations were carried out examining the interaction between IKKα and 
NIK. In both the alternative NF-κB activation and TLR7/8 pathway to IFN 
induction, a key step in initial induction is NIK-mediated activation of IKKα. We 
have shown the NIK-IKKα interaction previously in Figure 8, and now tested 
whether disruption of DDX3 had any effect on this interaction. We carried out an 
immunoprecipitation using Flag-NIK and endogenous IKKα. IKKα clearly 
immunoprecipitated with Flag-NIK, however in the presence of the DDX3 
antagonist K7 this interaction was reduced (Figure 31).   
 
Figure 31: K7 reduces the interaction between NIK and IKKα.  
HEK293T cells were transfected with constructs for Flag-NIK and/or Ha-K7. Cell 
lysates were subjected to immunoprecipitation (IP) with an anti-Flag antibody, 
followed by SDS-PAGE and WB analysis with the indicated antibodies (Shown is a 
representative experiment of 3 independent experiments).  
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A similar experiment was then carried out using DDX3 knockdown cells. This 
showed that in cells with reduced DDX3, the interaction between NIK and IKKα 
was also reduced (Figure 32). 
 
Figure 32: Knockdown of DDX3 reduces the interaction between NIK and 
IKKα. 
DDX3 knockdown was induced by the addition of 0.5 µg/ml doxycycline for 24 hrs 
to HEK293-TLR7 cells stably expressing either pTRIPZ shDDX3 or the 
corresponding non silencing control (NSC). Cells were then transfected with 
constructs for Flag-NIK or an empty vector control. Cell lysates were subjected to 
immunoprecipitation (IP) with an anti-Flag antibody, followed by SDS-PAGE and 
WB analysis with the indicated antibodies (Shown is a representative experiment of 
3 independent experiments).  
 
As DDX3 affected the interaction between NIK and IKKα and presumably the 
activation of IKKα by NIK, we also tested whether this affected the downstream 
interactors of IKKα. We carried out experiments to examine the interaction between 
IRF7 and IKKα, in which Flag-tagged IRF7 was expressed with or without Ha-
tagged K7 and immunoprecipitation was carried out using a Flag antibody. K7 
reduced the interaction between IRF7 and IKKα (Figure 33). This suggests that 
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disrupting the NIK-IKKα interaction has further downstream effects, or that DDX3 
may separately mediate IKKα interactions with a number of proteins, including NIK 
and IRF7. 
 
 
 
Figure 33: K7 reduces the interaction between IKKα and IRF7.  
HEK293T cells were transfected with constructs for Flag-IRF7 and/or Ha-K7 as 
indicated. Cell lysates were subjected to immunoprecipitation (IP) with an anti-Flag 
antibody, followed by SDS-PAGE and WB analysis with the indicated antibodies 
(Shown is a representative experiment of 3 independent experiments).  
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3.5.1 Summary  
Here we have attempted to elucidate the mechanism by which DDX3 exerts its 
effects on the IKKα mediated signalling pathways we investigated. We showed that 
K7 can disrupt the interactions between IKKα and NIK or IRF7. Additionally, we 
have shown that knockdown of endogenous DDX3 reduced the interaction between 
IKKα and NIK. This suggests that DDX3 may act as a bridging protein to bring 
IKKα in close proximity to other proteins. 
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3.6 DDX3  phosphorylation  by  the  IKKs  and  IKK  related  kinases  
When both IKKα and DDX3 were expressed together, we observed a marked shift in 
the band for DDX3 (Figure 7). As DDX3 has already been shown to be 
phosphorylated by the IKK related kinases IKKε and TBK1 (Soulat et al. 2008; Gu 
et al. 2013) we first compared the effects of the IKKs with the effects of IKK-related 
kinases on DDX3 phosphorylation by expressing Myc-DDX3 along with either 
IKKα, IKKβ, TBK1, IKKε or NIK (Figure 34). 
 
Figure 34: Higher molecular weight forms of DDX3 are observed in the 
presence of the IKKs and IKK related kinases.  
HEK293T cells were transfected with a plasmid vector for Myc-DDX3 and one of 
the indicated Flag-tagged kinases. 24h after transfection cell lysates were prepared 
and subjected to SDS-PAGE and WB analysis with the indicated antibodies (Shown 
is a representative experiment of 10 independent experiments). 
 
Interestingly the pattern of these higher molecular weight forms of DDX3 was 
different with each kinase. A shift was observed with IKKα, IKKβ and IKKε, while 
no strong shift was observed in the presence of NIK or TBK1 (Figure 34). While the 
shift induced with IKKε appeared as a smear, the shift induced by IKKα/β was a 
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clearer defined band suggesting the phosphorylation pattern of these kinases were 
different. 
We next carried out radioactive kinases assays using recombinant His-DDX3 and 
recombinant GST-kinases to confirm that the observed modification was indeed 
phosphorylation. The truncation mutant DDX3 (aa 1-408) was used, as we had 
previously shown that IKKα and IKKε interact with this region of DDX3 (Figure 
10) (Gu et al. 2013). DDX3 (aa 5-175) was also used as this had been shown to be 
strongly phosphorylated by IKKε (Gu et al. 2013). 
 
Figure 35: DDX3 is phosphorylated by IKKα, IKKβ and IKKε but not NIK. 
Recombinant His-DDX3 (either 1-408 or 5-172) was incubated with recombinant 
GST-kinases as indicated in the presence of [γ-32P]ATP (left and right panels). 
GST-NIK was also incubated with its substrate IKKα in the presence of [γ-32P]ATP 
(middle panel). Samples were then subjected to SDS-PAGE and autoradiograph 
analysis, showing incorporation of [γ-32P]ATP (Shown is a representative 
experiment of 5 independent experiments). 
 
IKKε phosphorylated DDX3 1-408 and 5-172 strongly as expected, but so too did 
IKKα and IKKβ albeit at a slightly lower level (Figure 35). NIK however, did not 
induce any phosphorylation of DDX3 (Figure 35). We therefore confirmed that the 
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NIK protein was active, by carrying out an assay with its substrate IKKα, showing 
that NIK could phosphorylate IKKα in the same experiment (middle panel).  
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We also carried out similar kinase assays to determine whether the DDX3 antagonist 
K7 could affect this phosphorylation of DDX by IKKα. In this assay we used GST-
IKKα and DDX3 (aa 1-408) with and without the addition of K7 or an unrelated 
control protein Rab14. We showed that K7 could reduce the phosphorylation of 
DDX3 by IKKα, while the addition of the Rab14 control protein had no effect on 
IKKα mediated phosphorylation of DDX3 (Figure 36). 
 
Figure 36: K7 inhibits the phosphorylation of DDX3 by IKKα.  
Recombinant GST-IKKα was incubated with recombinant His-DDX3 (1-408) in the 
presence of [γ-32P]ATP and recombinant His-K7 or the unrelated control protein 
His-Rab14. Samples were then subjected to SDS-PAGE and autoradiograph analysis 
showing incorporation of [γ-32P]ATP. Total amounts of recombinant proteins were 
visualized by Coomassie staining (Shown is a representative experiment of 3 
independent experiments). 
 
As we observed differing patterns of shifts and levels of phosphorylation induced by 
the different kinases (Figure 34, Figure 35), this suggested that the residues being 
phosphorylated were not the same for each kinase. Phospho-proteomics work on the 
phosphorylation of DDX3 by IKKε indicated a number of residues that were 
phosphorylated by IKKε (Gu et al. 2013). As part of this screen, Dr. Lili Gu in our 
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lab produced a number of DDX3 serine to alanine mutants. Single alanine mutants 
were produced for S71, S102, and S152, a double mutant for S82 and S83 (2A 
mutant), a triple mutant for S82, S83 and S102 (3A mutant), and a quadruple mutant 
for S82, S83, S102 and S71 (4A mutant). We carried out radioactive kinase assays 
using these mutants to compare how DDX3 phosphorylation by IKKα or IKKε is 
impacted by these mutations (Figure 37). 
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Figure 37: IKKα phosphorylates DDX3 on multiple sites.  
Recombinant GST-IKKα (A) or GST-IKKε (B) were incubated with recombinant 
wild-type (wt) His-DDX3 (1–408) or the indicated DDX3(1–408) alanine mutants in 
the presence of [γ-32P]ATP. Samples were then subjected to SDS-PAGE and 
autoradiograph analysis. Total amounts of His-DDX3 mutants were visualized by 
Coomassie staining. The top panel in both A and B shows results of one 
representative experiment out of four. For each repeat experiment, the intensity of 
autoradiograph and Coomassie-stained bands was quantified using ImageJ software. 
Values for autoradiograph bands were normalized to the intensity of the 
corresponding Coomassie-stained bands to account for differences in protein 
loading. The normalized signal for DDX 3(1–408) was set to 1 in each case. Data in 
the lower panel in both A and B are presented as means +/- standard deviations from 
four independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 [all 
compared to wt DDX3(1–408)] by an unpaired Student's t test. 
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In Dr. Gu’s work, phosphorylation of serine 102 of DDX3 was shown to be essential 
for IKKε mediated IFNβ induction (Gu et al. 2013). In radioactive kinase assays, 
mutation of S102 to alanine does not impact IKKα phosphorylation as much as IKKε 
phosphorylation (Figure 37). The S71 and S152 mutants both show approximately a 
75% reduction in phosphorylation by IKKα when compared to wt DDX3, however 
the S102 mutant did not show a significant difference (Figure 37). The 2A mutant 
showed approximately a 60% reduction in phosphorylation, the addition of the S102 
mutation in the 3A mutant did not change this reduction, while addition of the S71 
mutation in the 4A mutant reduced the phosphorylation further (Figure 37). For 
IKKε all the mutations showed a significant difference compared to wt DDX3 
(Figure 37). 
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To confirm the difference between IKKα and IKKε with respect to the S102 residue, 
individual kinase assays were carried out using the DDX (aa 80-408) truncation 
mutant and an 80-408 S102A mutant, in an effort to isolate effects from other 
phosphorylated residues (Figure 38). 
 
Figure 38: IKKα still strongly phosphorylates the S102A DDX3 alanine mutant.  
Recombinant GST-IKKα or GST-IKKε were incubated with recombinant wild-type 
(wt) His-DDX3(1–408), His-DDX3(100–408), His-DDX3(80–408), or the 
DDX3(80–408) S102A alanine mutants in the presence of [γ-32P]ATP. Samples 
were then subjected to SDS-PAGE and autoradiograph analysis with the indicated 
antibodies (Shown is a representative experiment of 3 independent experiments). 
Right panel produced by Lili Gu – host pathogen interaction lab (Gu et al. 2013). 
 
While the DDX3 (aa 80-408) S102A mutant failed to be phosphorylated strongly by 
IKKε (Figure 38b) (Gu et al. 2013), this mutation did not appear to affect 
phosphorylation by IKKα (Figure 38a).  
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As the S71A mutant seemed to have significantly reduced phosphorylation levels 
compared to wt DDX3 in the case of both IKKε and IKKα, and there was an S71-
phospho-DDX3 antibody available (kindly donated by Sir Philip Cohen, MRC 
phosphorylation Unit, University of Dundee), experiments were carried out to study 
DDX3 S71 phosphorylation in HEK293T cells. Flag-tagged IKKα, IKKβ, IKKε or 
TBK1 were expressed along with DDX3 (aa 1-408) or DDX3 (aa 1-408)-S71A and 
samples were probed using the phospho-S71 specific DDX3 antibody (Figure 39). 
 
Figure 39: Both IKKα and IKKε phosphorylate DDX3 on serine 71.  
HEK293T cells were transfected with a plasmid vector for wt Ha-DDX3 or the 
mutated S71A DDX3 and one of the indicated Flag-tagged kinases. 24h after 
transfection, cell lysates were prepared and subjected to SDS-PAGE and WB 
analysis with the indicated antibodies (Shown is a representative experiment of 3 
independent experiments).  
 
 
While both IKKα and IKKε did phosphorylate serine 71 of DDX3, the 
phosphorylation by IKKε was a lot stronger, while IKKα only induced a moderate 
increase in the band intensity for S71 (Figure 39). 
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In the course of these investigations we also carried out luciferase assays using the 
same serine to alanine DDX3 constructs we used in Figure 37. As the 
phosphorylation of DDX3 by IKKα was clearly affected upon mutation of these 
residues, we sought to clarify if this had any functional consequences on IFNα4 and 
IFNβ promoter induction. However, no significant differences in IFNα4 or IFNβ 
induction was apparent downstream of NIK/IKKα or CLO75 stimulation (Figure 40, 
Figure 41, Figure 42, Figure 43). In the case of IFNβ induction downstream of 
NIK/IKKα there did seem to be a trend of reduced IFNβ induction with a number of 
the DDX3 serine to alanine mutants compared to wt DDX3 (Figure 40) but they did 
not reach significance.  
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Figure 40: Mutation of serines on DDX3 does not affect IFNβ induction 
downstream of NIK/IKKα. 
HEK293R1 cells were transfected with an ifnb promoter reporter gene construct and 
expression constructs for Flag-IKKα and Flag-NIK or empty vector controls along 
with the indicated DDX3 alanine mutants 24h after transfection cells were harvested 
and measured. Data for reporter gene assays are expressed as mean fold induction 
relative to control levels. A representative experiment from 6 independent 
experiments is shown, with each experiment performed in triplicate. Data are 
presented as means +/- standard deviations. 
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Figure 41: Mutation of serines on DDX3 does not affect IFNβ induction 
downstream of CLO75 stimulation.  
HEK293-TLR7 cells were transfected with an ifnb promoter reporter gene construct 
and expression constructs for the indicated DDX3 alanine mutants or empty vector 
control. 24h after transfection cells were stimulated with CLO75 as indicated for 
24h. Cells were then harvested and luciferase activity was measured. Data for 
reporter gene assays are expressed as mean fold induction relative to control levels. 
A representative experiment from 6 independent experiments is shown, with each 
experiment performed in triplicate. Data are presented as means +/- standard 
deviations. 
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Figure 42: Mutation of serines on DDX3 does not affect IFNα4 induction 
downstream of NIK/IKKα.  
HEK293R1 cells were transfected with an ifna4 promoter reporter gene construct 
and expression constructs for Flag-IKKα/NIK or empty vector controls along with 
the indicated DDX3 alanine mutants 24h after transfection cells were harvested and 
measured. Data for reporter gene assays are expressed as mean fold induction 
relative to control levels. A representative experiment from 6 independent 
experiments is shown, with each experiment performed in triplicate. Data are 
presented as means +/- standard deviations. 
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Figure 43: Mutation of serines on DDX3 does not affect IFNα4 induction 
downstream of CLO75 stimulation.  
HEK293-TLR7 cells were transfected with an ifna4 promoter reporter gene construct 
and expression constructs for the indicated DDX3 alanine mutants or empty vector 
control. 24h after transfection cells were stimulated with CLO75 as indicated for 
24H. Cells were then harvested and luciferase activity was measured. Data for 
reporter gene assays are expressed as mean fold induction relative to control levels. 
A representative experiment from 6 independent experiments is shown, with each 
experiment performed in triplicate. Data are presented as means +/- standard 
deviations. 
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Due to the above results, we next aimed to determine whether IKKα phosphorylates 
different serine residues in DDX3. Thus, we carried out phosphoproteomics analysis 
to determine the specific residues that are phosphorylated by IKKα. We carried out 
phosphorylation site mapping by mass spectrometry. For this analysis, we used 
DDX3 (1–408) that had been phosphorylated in vitro using recombinant IKKα. We 
separated the phosphorylated protein by SDS-PAGE and carried out a tryptic digest 
of the protein band, followed by analysis of the tryptic peptides by ion trap mass 
spectrometry (IT-MS). This analysis showed that phosphorylated residues were 
present at position S2, S23, S71, S86 and S152 (Table 5). 
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Phosphorylated 
residues 
Peptide sequence IKKα  Peptide 
Sequence 
IKKε 
S2 or S23 MSHVAVENALGLD
QQFAGLDLNSSDNQ
SGGSTASK 
    
S23 or 24 MSHVAVENALGLDQ
QFAGLDLNSSDNQS
GGSTASK 
    
S70 or S71 or 
S74 
DKDAYSSFGsR   K.DKDAYSSF
GSR.S 
  
S82 or S83 or 
S86 
  R.GKSSFFSDR.
G 
  
S86 SSFFSDR     
S102 or S109   R.GRSDYDGIG
SR.G 
  
S152 LEQELFSGGNTGINF
EK 
  R.LEQELFSGG
NTGINFEK.Y 
  
Table 5: DDX3 is phosphorylated by IKKα on distinct residues from IKKε. 
Showing phosphopeptides identified in IT-MSMS analysis of recombinant DDX3 
(aa 1-408) phosphorylated by either IKKα (this study) or IKKε (Gu et al. 2013). 
 
 
Figure 44: Cartoon representation of phosphorylation sites in the N-terminal 
region of DDX3 
Showing IKKα phosphorylation sites in red, IKKε sites in yellow and sites that are 
phosphorylated by both kinases in green. 
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While the residues S152 and S71 were also detected in the IKKε screen, the other 
three residues S2, S23 and S86 were unique to IKKα (Figure 44). Therefore serine 
to alanine substitution mutants for each of these residues were generated along with 
a double mutant of S71A, S152A, a triple mutant of S71A, S152A and S23A, and a 
quadruple mutant of S71A, S152A, S23A and S2A. These substitution mutants were 
used in luciferase reporter assays to determine if there was a functional defect in 
DDX3 with these mutated serines (Figure 45, Figure 46, Figure 47, Figure 48). 
While single mutations of DDX3 showed no significant differences in IFNβ or 
IFNα4 promoter induction downstream of NIK/IKKα or CLO75 stimulation (not 
shown), there was a marked difference in IFN induction with some of the 
combination serine to alanine mutants. Although only preliminary results, it 
appeared that a triple mutant of S71A, S152A and S23A resulted in a slightly 
decreased enhancement of IFNβ and IFNα4 promoter induction compared to wt 
DDX3 (Figure 45, Figure 46, Figure 47, Figure 48). However the addition of the 
S2A mutation to this triple mutant appeared to negate this effect and actually 
enhanced the induction of IFN far above that of wt DDX3 (Figure 46, Figure 47, 
Figure 48), except in the case of IFNβ induction downstream of NIK/IKKα where it 
did the opposite and appeared to inhibit induction of IFNβ (Figure 45).  
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Figure 45: Mutation of serines on DDX3 affects IFNβ induction downstream of 
NIK/IKKα. 
HEK293R1 cells were transfected with an ifnb promoter reporter gene construct and 
expression constructs for Flag-IKKα/NIK or empty vector controls along with the 
indicated DDX3 alanine mutants 24h after transfection cells were harvested and 
measured. Data for reporter gene assays are expressed as mean fold induction 
relative to control levels with the values averaged from 2 independent experiments, 
with each experiment performed in triplicate. 
 
  
144 
 
 
 
 
Figure 46: Mutation of serines on DDX3 affects IFNb induction downstream of 
CLO75 stimulation.  
HEK293-TLR7 cells were transfected with an ifnb promoter reporter gene construct 
and expression constructs for the indicated DDX3 alanine mutants or empty vector 
control. 24h after transfection cells were stimulated with CLO75 as indicated for 
24H. Cells were then harvested and luciferase activity was measured. Data for 
reporter gene assays are expressed as mean fold induction relative to control levels 
with the values averaged from 3 independent experiments, with each experiment 
performed in triplicate. 
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Figure 47: Mutation of serines on DDX3 affects IFNα4 induction downstream of 
NIK/IKKα.  
HEK293R1 cells were transfected with an ifna4 promoter reporter gene construct 
and expression constructs for Flag-IKKα/NIK or empty vector controls along with 
the indicated DDX3 alanine mutants 24h after transfection cells were harvested and 
measured. Data for reporter gene assays are expressed as mean fold induction 
relative to control levels with the values averaged from 2independent experiments, 
with each experiment performed in triplicate. 
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Figure 48: Mutation of serines on DDX3 affects IFNa4 induction downstream of 
CLO75 stimulation.  
HEK293-TLR7 cells were transfected with an ifna4 promoter reporter gene construct 
and expression constructs for the indicated DDX3 alanine mutants or empty vector 
control. 24h after transfection cells were stimulated with CLO75 as indicated for 
24H. Cells were then harvested and luciferase activity was measured. Data for 
reporter gene assays are expressed as mean fold induction relative to control levels 
with the values averaged from 3 independent experiments, with each experiment 
performed in triplicate. 
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3.6.1 Summary  
In addition to investigating the effects DDX3 has on IKKα, we have investigated the 
effects IKKα has on DDX3. We initially observed a shift of DDX3 in western blots 
when co-expressed with IKKα in a pattern that was dissimilar to that of IKKε. We 
showed here that DDX3 is phosphorylated by IKKα. We have also demonstrated that 
while IKKα and IKKε share some target serine residues on DDX3, there are residues 
that are unique to each kinase. Phosphorylation of Ser102 appears to be unique to 
IKKε, while the Ser2 and S23 residues appear unique to IKKα, and Ser71, S86, S152 
being common to both. We have also begun to investigate the functional effects of 
IKKα phosphorylation but have yet to obtain conclusive results. 
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3.7 Using   Blue-­‐Native   PAGE   for   the   isolation   of  Multi-­‐Protein  
complexes    
3.7.1 Introduction    
This section, in addition to providing results from Blue Native PAGE experiments 
(sections 3.7.3 and 3.7.4.2) also explains the theory, methods, and considerations 
used in carrying out this work (sections 3.7.1.1, 3.7.1.2, 3.7.1.3, and 3.7.2). 
3.7.1.1 Multi-­‐Protein  Complexes  
Multi-protein complexes (MPCs) are an essential part of signalling pathways within 
the cell. The regulation and propagation of a signal requires protein-protein 
interactions, forming complexes ranging from simple pair-wise interactions to multi-
protein complexes containing many different proteins. The composition of these 
complexes can affect protein function and signalling pathways, subtly changing the 
type of response that is brought about by changes in the cell environment.  
Investigating MPCs is no trivial undertaking as their composition and stability can 
rapidly change due to a number of factors, for example, its location within the cell or 
the activation state of the cell, an example being the Myddosome that is formed upon 
TLR-ligand binding (Lin et al. 2010) (Section: 1.2.1.1.2). Composition of complexes 
can change within minutes of a receptor being engaged by its cognate stimulus. In 
addition, most proteins are involved in multiple distinct protein complexes and some 
might exist in both monomer and multimer form. 
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3.7.1.2 Investigating  Multi-­‐protein  complexes  -­‐  Blue  Native-­‐PAGE    
Blue-Native Polyacrylamide Gel Electrophoresis is a method to identify and analyse 
multi-protein complexes. Numerous methods have been developed to investigate 
protein-protein interactions, from simple co-immunoprecipitations, to wide scale 
screens of interactions such as Yeast 2-Hybrid screens or tandem affinity 
purification. However, for investigations of proteins in their native state there are 
fewer methods available. Native isoelectric focusing is one such method that 
separates proteins according to their isoelectric point, but some proteins are not 
soluble at their isoelectric point. Gel filtration is another commonly used method that 
can separate complexes according to their size, however BN-PAGE provides a much 
higher resolution.  
BN-PAGE can be used for a wide range of investigations. It was originally 
developed to isolate protein complexes from cell membranes (Schägger & von 
Jagow 1991) but has since been expanded to be used to investigate intracellular 
protein complex composition, complex sizes, and for other applications that require 
proteins to be separated in their native form (Swamy, Siegers, et al. 2006). The 
technique has also been further developed to incorporate a second dimension where 
the separated native complexes can be run in a reducing gel to separate out their 
constituent components, further expanding its usefulness (Wittig et al. 2006).  
There are a number of advantages to using BN-PAGE for our investigations. It 
permits us to look at a wide range of complexes ranging in size from 10kD to 10MD. 
It allows us to determine the approximate size, subunit composition and relative 
abundance of the complexes. Additionally, it can allow us to determine the presence 
of monomeric forms of a protein, e.g. whether a protein of interest is present in 
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multiple complexes simultaneously or whether the composition of the complexes 
changes upon stimulation. A further advantage is that it is possible to distinguish 
between interactions that are direct or bridged by another protein e.g. between A-B, 
A-C, B-C, and A-B-C complexes. The BN-PAGE method can be expanded upon for 
different types of investigations, for example the NAMOS assay which is a “Native 
Antibody-based Mobility Shift technique”, is used taking advantage of the native 
nature of the BN-PAGE gels to determine the stoichiometry of protein complexes 
(Swamy et al. 2007). As with all techniques however there are disadvantages: the 
MPCs being studied must be in abundance – those that are present in small amounts 
can be difficult to visualise. The method is quite sensitive, great care must be taken 
to avoid any SDS contamination at every step so as to not disrupt the complexes of 
interest. It is important to determine the optimum detergent/lysis conditions for every 
new investigation as the stabilities of complexes can vary greatly. 
3.7.1.3 Principle  of  BN-­‐PAGE  
In normal SDS-PAGE, denatured proteins are coated in SDS so that the proteins are 
given a charge in relation to its size. Without this, the proteins’ charge is mostly 
dependent on its amino acid composition and not directly proportional to its size. 
When running native gels the same problem arises, but instead of SDS the anionic 
dye Coomassie Blue G-250 is used. It performs a similar role to the SDS in that it 
binds non-specifically to all proteins and coats it in a negative charge, allowing it to 
migrate towards the anode when running the gel, even at a neutral pH of 7.5. The 
Coomassie Blue G-250 does not act as a detergent and preserves the structure of the 
complexes. It also reduces the risk of denaturation and protein aggregation, as the 
negatively charged complexes will repel each other. It is hydrophobic enough that it 
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can bind to membrane proteins but is also sufficiently soluble in water (Schägger et 
al. 1994). 
 
While the first dimension Blue-Native gel separates the intact protein complexes 
according to their size, a second dimension denaturing gel can separate out the 
components of these complexes. The separated complexes in the native gel are 
placed in a reducing sample buffer, allowing the complexes to be separated out into 
their individual protein components in a standard SDS-PAGE gel. This can show, for 
example, the composition of particular complexes (Figure 49).  
 
 
Figure 49: Principle of first and second dimension BN-PAGE  
The first dimension BN-PAGE separates whole complexes according to their relative 
sizes, the second dimension is a denaturing SDS-PAGE gel which separates out the 
components of the individual complexes. Figure from (Fiala et al. 2011). 
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3.7.2 Establishing  conditions  for  BN-­‐PAGE  experiments  
3.7.2.1 Co-­‐Immunoprecipitations  
In carrying out our previous co-immunoprecipitations we obtained two key points of 
information for our BN-PAGE experiments. The first is that the complexes are 
abundant enough to be detected and secondly it provided a starting point for the 
buffer conditions under which the complexes of interest may be stable. In previous 
experiments, DDX3 was successfully co-immunoprecipitated with another protein of 
interest using Triton X-100 as the detergent. This implied that at least some of the 
complexes in which DDX3 is involved are abundant enough to be detected by BN-
PAGE. Also as Triton X-100 did not disrupt the interaction in normal co-
immunoprecipitations, this was the first buffer used in carrying out BN-PAGE with 
DDX.  
3.7.2.2 Choice  of  detergent  
One of the most important things we had to consider in carrying out BN-PAGE is the 
choice of detergent to be used in the lysis buffer. A balance must be struck with it 
being strong enough to lyse the cells and solubilise the protein complexes 
effectively, while not disrupting the complex of interest. A non-ionic detergent must 
be chosen and samples must have a low ionic strength, as any cations present in the 
samples will react with the Coomassie in the running buffer, resulting in the 
precipitation of both the Coomassie and the protein in the sample, leading to 
impaired entry into the gel [Figure 50] (Camacho-Carvajal et al. 2004). For 
example, 50mM is the maximum tolerated concentration of sodium ions in the 
samples to allow them to successfully enter the gel (Swamy, Siegers, et al. 2006). 
When the ionic strength of a sample is too high it starts to precipitate out of solution 
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and does not enter the gel correctly (Figure 50) lanes (A,B). This can be 
counteracted by running a smaller amount of sample (Figure 50) lane (C). 
 
Figure 50: The effect of running a sample with a high ionic strength  
Lanes A and B show precipitation of samples in gel wells as the ionic strength was 
too high resulting in impaired entry into the gel. Lane C shows that this can be 
counteracted by running a smaller amount of sample. HEK293T cells were lysed in a 
0.1% Triton X-100 lysis buffer, dialysed for 6 hours and run on a 4-10% gradient 
BN-PAGE Gel A -40µl, B – 20µl, C- 10µl. 
 
Common detergents used for BN-PAGE include: digitonin 0.5-1% - one of the 
mildest detergents, dodecylmaltoside 0.1-0.5% -also a mild detergent but slightly 
stronger, disrupting some of the weaker hydrophobic interactions, Brij 96 0.1-0.5%, 
and Triton X-100 0.1-0.5% - under higher concentrations Triton X-100 can 
solubilise membrane proteins. 
A number of things can be done to reduce the ion concentration, including dialysis 
and immunoprecipitation followed by native elution from the beads (which has the 
added benefit of concentrating the complex of interest). The second aspect to take 
into consideration is the concentration of protein in the sample. This is tied with the 
ionic concentration of the sample and detergent choice. If the concentration of 
protein is too high it is more likely to precipitate out while running the gel. The 
A B C 
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protein samples start to precipitate out of the gel as it reaches the lower parts of the 
gel with a smaller pore size (Figure 51), but if the protein concentration is too low it 
may be below the detection limit.  
 
 
Figure 51: The effect of having protein and/or detergent concentration that is 
too high. 
HEK293T cells were lysed in a 0.5% Triton X-100 lysis buffer, dialysed overnight 
and run on a 4-10% gradient BN-PAGE Gel, subsequent western blotting and 
probing with DDX3 antibody [Santa Cruz] was carried out.  
 
  
155 
 
Initial experiments were carried out to test several different detergents at various 
concentrations along with varying cell numbers. The best detergent was determined 
to be Triton X-100 at a concentration of 0.1% and the ideal cell number was 
determined to be between 500,000 and 800,000. The combination of these two 
conditions gave the best detectability of DDX3 from cell lysates and did not result in 
the precipitation of samples as they ran through the gel (Figure 52). It can be seen 
that a 0.5% Triton X-100 lysis buffer resulted in the sample precipitating out near the 
bottom of the gel (Figure 52). 
 
Figure 52: Showing the best conditions for BN-PAGE for DDX3 
HEK293T cells were lysed in either a 0.5% or a 0.1% Triton X-100 lysis buffer, 
dialysed overnight and run on a 4-10% gradient BN-PAGE Gel, subsequent western 
blotting and probing with DDX3 antibody [Santa Cruz] was carried out. 
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3.7.3 Aim  
We wanted to explore BN-PAGE in order to investigate the multi-protein complexes 
that DDX3 might be involved in within the cell and to determine whether these 
complexes change with stimulation. It should also allow us to investigate whether 
DDX3 exist as a monomer or if higher order complexes exist. 
 
Previous work showed that stimulation-induced complexes could not be resolved 
(Swamy, Kulathu, et al. 2006). However, we tried to optimise the technique and 
attempted to see if the complexes that DDX3 is part of change with Sendai Virus 
(SeV) stimulation. We chose Sendai Virus stimulation, as the role of DDX3 in RIG-I 
signalling is well established and SeV strongly triggers this pathway. This therefore 
gives us the best chance at detecting possible changes in DDX3-containing 
complexes. 
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3.7.4 Results  
3.7.4.1 Stimulation  induced  changes  in  DDX3  complexes.  
After establishing the conditions necessary to investigate DDX3-containing 
complexes, we next carried out a comparison of stimulated and unstimulated 
samples. 24h of SeV stimulation resulted in an increase in the number of bands of 
DDX3 in the native gels. In unstimulated cells, DDX3 was mostly in one lower size 
band with some higher bands barely detectable. In the stimulated sample DDX3 
seemed to shift from this lower sized band and redistributed to the higher bands 
(Figure 53).  
 
 
Figure 53: DDX3 redistributes into higher molecular weight bands upon Sendai 
virus stimulation. 
Unstimulated and SeV stimulated (24h) HEK293T cells were lysed in a 0.1% Triton 
X-100 lysis buffer, dialysed for 6 hours and run on a 4-10% gradient BN-PAGE Gel. 
Subsequent western blotting and probing with DDX3 antibody [Santa Cruz] was 
carried out. Arrows show the redistribution of DDX3 in the stimulated sample 
(Shown is a representative experiment of 3 independent experiments).  
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To further confirm that the observed bands indeed contained DDX3, we carried out a 
second dimension SDS-page gel in addition to a first dimension BN-PAGE gel. As 
some sample is lost upon carrying out the second dimension, we used both a sample 
using 0.5 million cells (sample D) and one with a higher number cells (2 million) 
(Sample A). Sample A resulted in a streak in the second dimension which is a result 
of having a protein concentration that is too high, while in sample D the 2 bands that 
were apparent in unstimulated cells also gave 2 bands at a molecular weight of 72 in 
the second dimension denaturing gel, confirming the fact that this was indeed DDX3 
(Figure 54).  
 
Figure 54: DDX3 appears as two distinct bands in unstimulated cells. 
Unstimulated HEK293T cells were lysed in a 0.1% Triton X-100 lysis buffer, 
dialysed overnight and run on a 4-10% gradient BN-PAGE Gel, subsequent western 
blotting and probing with DDX3 antibody [Santa Cruz] was carried out [Left Panel] 
(Shown is a representative experiment of 3 independent experiments). In addition a 
second dimension SDS-PAGE gel was carried out on samples A and D [Right 
Panels].  
1st Dimension 
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To get a better picture of the changes in DDX3 containing complexes upon 
stimulation, we carried out experiments with shorter SeV stimulation times. It 
became apparent that while DDX3 appears as two bands in unstimulated samples 
this increases to 4 bands after 1 hour of SeV stimulation. These higher bands 
decrease in intensity at 2h and 4h (Figure 55). 
 
Figure 55: DDX3 changes its banding pattern upon short SeV stimulation. 
Unstimulated and SeV stimulated HEK293T cells were lysed in a 0.1% Triton X-100  
lysis buffer, dialysed overnight and run on a 4-10% gradient BN-PAGE Gel, 
subsequent western blotting and probing with DDX3 antibody [Santa Cruz] was 
carried out. Arrows show the redistribution of DDX3 in the stimulated samples 
(Shown is a representative experiment of 3 independent experiments).  
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To determine if the observed higher bands were indeed due to DDX3 being involved 
in multiple complexes, half of a sample was boiled in SDS and simultaneously run 
on a BN-PAGE gel along with the other non-boiled half. This was done to disrupt 
any complexes that were present. In the boiled samples only 2 bands remained, this 
suggests that the bottom two bands may represent the monomer of DDX3 and 
possibly a posttranslationally modified form of DDX3 (Figure 56) due to the SeV 
stimulation. 
 
 
Figure 56: The higher sized bands containing DDX3 disappear upon boiling 
samples with SDS.  
Unstimulated and SeV stimulated HEK293T cells were lysed in a 0.1% Triton X-100 
lysis buffer, dialysed for 6 hours, half of each sample was taken and boiled in the 
presence of SDS and run alongside the non-boiled samples on a 4-10% gradient BN-
PAGE Gel, subsequent western blotting and probing with DDX3 antibody [Santa 
Cruz] was carried out. Arrows show the redistribution of DDX3 in the stimulated un-
boiled samples. 
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3.7.4.2 Investigation  of  DDX3  oligomers  
In addition to our studies on native DDX3 containing complexes in response to SeV 
stimulation, we investigated the possibility that DDX3 exists as an oligomer. To 
achieve this we ran purified recombinant His-DDX3 on a BN-PAGE gel. Four bands 
that corresponded approximately to multiples of DDX3s size were observed (DDX3 
MW=72kDa). 
 
Figure 57: DDX3 may exist as monomer, dimer, trimer and tetramer species.  
Purified recombinant His-DDX3 was dialysed overnight and run on a 4-10% 
gradient BN-PAGE Gel, subsequent western blotting and probing with DDX3 
antibody [Santa Cruz] was carried out. Arrows show bands corresponding to 
multiples of the size of DDX3 (Shown is a representative experiment of 2 
independent experiments). 
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3.7.5 Summary  
Here we have used the BN-PAGE method to investigate DDX3 containing 
complexes. With DDX3 interacting with a number of different signalling mediators, 
we sought to investigate what complexes are formed and what proteins are involved. 
Ur results suggest that DDX3 is primarily in 2 main complexes in unstimulated cells 
[Figure 54]. Subsequent experiments involving boiling samples in SDS indicated 
that this may not in fact be complexes. It instead implied that the higher band was a 
post-translationally modified form of DDX3, with the majority being a free 
monomeric species [Figure 56]. The pair of bands was still present after 
denaturation in the stimulated samples, while only one band was present in the 
boiled unstimulated sample that corresponded to the size of DDX3 protein.  
The pattern of banding did change upon SeV stimulation, the lower of the two main 
bands seen in the unstimulated sample appeared to redistribute to higher molecular 
weight bands. With increasing stimulation time however these higher bands seemed 
to reduce in intensity. This suggests that DDX is moving to different complexes 
upon stimulation and is dissociating from these complexes by the 2 hour time point 
and reverting back to its resting state. It cannot be excluded however that these 
higher molecular weight complexes are not simply multimers of DDX3 without 
further investigation, it would be interesting to further examine the stoichiometry of 
these DDX3 containing complexes, for example by using the NAMOs assay.  
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4 Discussion  
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4.1 The  effect  of  DDX3  on  IKKα  activity  
In this work we aimed to investigate a possible relationship between DDX3 and the 
kinase IKKα. As DDX3 had previously been shown to be an interaction partner of 
IKKε (Schröder et al. 2008) and TBK1 (Soulat et al. 2008), we decided to 
investigate potential interactions with proteins that are closely related to these 
kinases. IKKα drew our interest as it is involved in multiple important immune 
signalling pathways and is highly similar to IKKε, showing a 28% aa identity and 
45% similarity. A possible interaction with NIK was also investigated as it is a 
kinase that is known to regulate IKKα in the signalling pathways we are interested 
in. 
We have here established that DDX3 is a direct interaction partner of IKKα. 
However, while both IKKα and NIK successfully co-immunoprecipitated with 
DDX3 in overexpression experiments, this experimental set-up does not demonstrate 
a direct interaction, and the possibility that the interactions are bridged by another 
protein could not be excluded. In carrying out His-pulldown assays we were able to 
show that there was a direct interaction between IKKα and DDX3. We also 
narrowed down the region of DDX3 that IKKα interacts with, using DDX3 
truncation mutants. In co-immunoprecipitation studies in cells, we showed that IKKα 
co-immunoprecipitates with the N-terminal region aa 1-408 region of DDX3. This 
was confirmed in work carried out by Dr. Lili Gu in our lab, that showed a direct 
interaction between IKKα and the region between aa 139 and 172 of DDX3. This is 
in contrast to data on the interaction between DDX3 and IKKε recently published by 
our lab (Gu et al. 2013). This data suggested that there were at least two sites of 
IKKε interaction on DDX3, one in the C-terminal region aa 409-662 of DDX3 and 
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one in the N-terminal aa 1-139 region, with no interaction demonstrated with the aa 
139-408 truncation mutant. In the case of IKKα, our data shows that it does not 
interact with the C-terminal aa 409-662 region of DDX3 but can still interact with an 
aa 139-408 DDX3 truncation mutant. This suggests that there is at least one site of 
interaction for IKKα on the N-terminus of DDX3 and that there are functional 
differences in the interactions between IKKα-DDX3 and IKKε-DDX3. 
We have also shown that this interaction can be detected at an endogenous level and 
can be induced following stimulation with the TLR7/8 ligand CLO75. Our work 
showing the DDX3 and IKKα interaction is backed up in a recent paper by Li et al. 
that showed an interaction between IKKα and DDX3 was induced by poly(I:C) 
transfection or HCV infection in Huh 7.5.1 cells (Li et al. 2013). These data confirm 
that the interaction is relevant in the context of immune signalling in the response to 
viral infection.  
Following on from demonstrating this interaction we have shown that DDX3 can 
enhance the kinase activity of IKKα. We have previously shown that DDX3 
facilitates the auto-phosphorylation and auto-activation of IKKε (Gu et al. 2013). 
Here we have shown that DDX3 has a similar effect on IKKα. DDX3 also enhances 
IKKα auto-phosphorylation, including phosphorylation of serines 176/180 located in 
its activation loop, which is known to activate IKKα in certain contexts (Mercurio 
1997). IKKα phosphorylation on Ser176/180 was inducible by CLO75 stimulation 
and peaked after 1 hour of stimulation, this was clearly reduced in DDX3 
knockdown cells. However IKKα phosphorylation was observable at the 4 hour 
stimulation timepoint suggesting that IKKα activation could still occur, albeit in a 
somewhat delayed manner. The fact that there were some residual levels of DDX3 in 
the knockdown cells may contribute to this observed IKKα phosphorylation, but 
166 
 
IKKα may simply be activated via an alternative means that is independent of DDX3 
but is involved in a later phase of signalling. 
The observations that DDX3 directly interacts with IKKα and enhances its 
phosphorylation, including phosphorylation in its activation loop, led us to 
investigate possible effects this interaction may have on pathways that are mediated 
by IKKα.   
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4.2 DDX3  enhances  signalling  downstream  of  IKKα    
Two important immune signalling pathways mediated by IKKα are the TLR7 
pathway to IFN induction and the alternative NF-κB pathway. We have shown that 
the increased activation of IKKα facilitated by DDX3 can result in augmented 
phosphorylation of its downstream targets, which results in amplified activation of 
these signalling pathways.  
We have shown that DDX3 enhanced p100 processing in the alternative NF-κB 
pathway and that knockdown of DDX3 reduced both IKKα phosphorylation in its 
activation loop and p100 phosphorylation which is required for its processing. This, 
as expected, led to reduced p100 processing to p52 and therefore reduced signalling 
in this pathway overall. This enhancement of processing may simply be due to the 
enhancement of IKKα activity by DDX3, but it is also possible that DDX3 may 
strengthen the interaction between IKKα and p100, as we have shown that DDX3 is 
constitutively in complex with p100, while the interaction with IKKα is inducible. 
However, it is clear that DDX3 has a role as a positive regulator of p100 processing 
and therefore the alternative NF-κB pathway as a whole. As the genes regulated by 
the alternative NF-κB pathway include those involved in cell cycle progression like 
skp2 (Schneider et al. 2006) and genes involved in development of lymphoid organs 
(Senftleben et al. 2001) this suggest that DDX3 may well play a role in development 
of lymphoid malignancies (Yu et al. 2012) and autoimmune disorders (Brown et al. 
2008). 
We have also implicated DDX3 as having a role in the TLR7-mediated pathway to 
IFN induction. Here, DDX3 also interacted with IRF7, which is a key transcription 
factor that leads to IFNα4 and IFNβ induction. Overexpression of DDX3 enhanced 
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induction of both of these IFNs downstream of NIK and IKKα and downstream of 
CLO75/TLR7 stimulation. We have shown that DDX3 can directly enhance 
phosphorylation of IRF7 by IKKα, which results in its activation, and leads to 
increased IFN induction. While we were not able to show significant differences in 
IFNα4 or IFNβ induction upon knockdown of DDX3, we did show that DDX3 
knockdown does reduce the interaction between IKKα and IRF7. It is possible that a 
significant difference in IFN induction upon knockdown of DDX3 could be observed 
with improved knockdown of DDX3 and more experimental repeats, as a trend of 
reduced IFN induction was observed. As DDX3 is not completely knocked down 
there may still be enough DDX present to enable a certain amount of IRF7 
signalling.  
While we have shown that the interaction between IKKα and DDX3 has an effect on 
these two signalling pathways, the study by (Li et al. 2013) showed that the IKKα-
DDX3 interaction results in an increased lipogenesis pathway induction also. The 
authors suggested that DDX3 acts to detect HCV 3’UTR RNA and recruits IKKα to 
induce IKKα mediated signalling. In this case IKKα activates CREB binding protein 
(CBP)/p300 which enhances SREBP-mediated lipogenesis and lipid droplet 
formation (Li et al. 2013). As HCV requires lipid droplets for its replication and 
assembly, this appears to enable viral infection. DDX3 has previously been shown to 
be required for HCV infection (Ariumi et al. 2007) and it is possible that this 
enhancement of IKKα activity may contribute to this effect.  
With this data combined with our own, DDX3 has now been implicated in at least 
three pathways that are mediated by IKKα, the alternative NF-κB, the TLR7 and the 
lipogenesis pathways. However, IKKα is a particularly interesting member of the 
IKK family. In addition to these roles of IKKα, it has also been implicated in a 
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number of other important signalling pathways, strengthening its position as a key 
regulator in innate immunity. It is traditionally known for its involvement in the 
canonical NF-κB pathway but interestingly, a number of activities that are 
independent of its direct activity with NF-κB have also become apparent. IKKα has 
been shown to have roles in the nucleus, for example, it can indirectly enhance NF-
κB activity through its phosphorylation of the SMRT co-repressor, resulting in the 
release of HDAC3 allowing NF-κB mediated transcription (Hoberg et al. 2004). It 
can also regulate chromatin remodelling, and therefore gene expression, by 
phosphorylating histone H3 serine 10 through its interaction with CBP (Yamamoto 
et al. 2003). It is also involved in crosstalk between NF-κB and the tumor suppressor 
protein p53, as IKKα phosphorylation of CBP switches its binding from p53 to NF-
κB. This shifting of the preference of CBP results in increased expression of NF-κB 
induced genes but a concurrent decreased expression of genes induced by 
p53(Huang et al. 2007). IKKα is also involved in cell cycle regulation, for example 
through its phosphorylation of β-catenin (Lamberti et al. 2001), ERα (Park et al. 
2005) and SRC3 (Wu et al. 2002), which promote cyclin D1 expression. IKKα can 
also phosphorylate cyclin D1 itself, which induces its degradation (Kwak et al. 2005) 
and thus possibly prevents it from being over-induced. As we have now shown that 
DDX3 plays a role in IKKα activation coupled with the fact that IKKα shows 
differing effects on a range of gene products it is clear that we are only yet scratching 
the surface of the varied effects IKKα may have and concurrently the role DDX3 
might have also. 
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4.3 DDX3  acts  as  a  scaffold  protein?  
There are now two reports suggesting that DDX3 acts as a PRR; Li et al. proposed 
that their observed interaction between DDX3 and IKKα occurs following direct 
recognition of HCV RNA by DDX3 (Li et al. 2013) and a paper by Oshiumi et al. 
(2010) suggested that DDX3 recognition of HCV RNA results in signalling via RIG-
I/mda-5/MAVS to induce IFN induction. In both cases DDX3 appears to act as a 
PRR to induce downstream signalling. However our data here and our previous 
studies have shown a role for DDX3 as a downstream signalling adaptor (Gu et al. 
2013). Several other studies in addition to our own have also shown a role for DDX3 
downstream of IKKε/TBK1 (Soulat et al. 2008; Wang & Ryu 2010; Yu et al. 2010; 
DeFilippis et al. 2010). My work now places DDX3 as being a signalling adaptor at 
the level of IKKα. We propose that DDX3 acts as a scaffold that facilitates protein-
protein interactions, for example, by bringing kinases in close proximity to their 
substrates. We have previously shown a role for DDX3 acting as a scaffold protein 
in IKKε-IRF3 signalling. IKKε interacts with and phosphorylates DDX3 Ser102 
which allows IRF3 recruitment, bringing it in close proximity to IKKε acilitating its 
activation (Gu et al. 2013). In this work we present evidence that DDX3 may 
function in a similar manner in the enhancement of IKKα-mediated pathways. 
We have seen some evidence in our BN-PAGE studies that DDX3 may form 
multimer species, as we have observed band sizes consistent with monomer, dimer, 
trimer and tetramer species of DDX3 in native gels. It is therefore conceivable that 
DDX3 could serve as a platform incorporating a number of different interactors. 
DDX3 acting as a scaffold could also be the mechanism whereby IKKα auto-
activation is increased. Even though DDX3 may possess only one IKKα binding site, 
171 
 
a multimer of DDX3 could still act to bring together IKKα proteins allowing them to 
phosphorylate each other. The closely related kinase, IKKβ, has previously been 
shown to possess dimerization domains and the residues present in this domain are 
also highly conserved in IKKα (Xu et al. 2011), which makes sense as IKKα and 
IKKβ can form both homodimers and heterodimers with each other. However the 
authors noted that the structure of the dimers did not allow the kinase domains to be 
in close proximity to allow transautophosphorylation. They suggested that higher 
order oligomers may facilitate the activation, as a tetramer formation showed more 
favourable proximity of kinase domains. They also proposed that NEMO may act as 
a scaffold to allow this to occur (Xu et al. 2011). DDX3 may act in a similar manner 
to facilitate the stabilisation of IKKα homo-dimers to allow 
transautophosphorylation to occur.  
While the functional relevance of the phosphorylation of DDX3 by IKKα is still 
unclear, it may also act in a similar way to the phosphorylation by IKKε, which 
facilitates the IRF3 interaction. Phosphorylation of DDX3 may change DDX3s 
potential interaction partners and therefore the substrates which are brought together 
with IKKα.  
Our evidence for DDX3 acting as a scaffold protein comes from the fact that the 
DDX3 antagonist K7 can inhibit many of the activating effects that we have shown 
for DDX3. K7 has previously been shown to mask two key residues that are essential 
for DDX3’s enhancement of IKKε induced IRF3 activation and ifnβ induction (Oda 
et al. 2009). The binding of K7 to DDX3 appears to block other interactions from 
occurring, as transfection of K7 reduced both IRF7-IKKα and NIK-IKKα 
interactions. We also have some preliminary data showing that NIK and DDX3 may 
also directly interact (not shown). This suggests that the observed co-
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immunoprecipitation between IKKα and NIK may in fact be bridged by DDX3, with 
both DDX3 and IKKα being pulled down when NIK was immunoprecipitated. In 
addition we have shown that knockdown of DDX3 results in a decreased NIK-IKKα 
interaction. As NIK is a known regulator of IKKα activity this obviously has 
implications for all pathways that they are involved in. The effects of DDX3 on the 
alternative NF-κB pathway and TLR7 pathway to IFN induction are also consistent 
with DDX3 acting as a scaffold protein. We have seen that DDX3 can interact with 
numerous proteins that are in these pathways, such as p100, p52 and p65 in the 
alternative NF-κB pathway, IRF7 in TLR7 signalling, in addition to IKKα and NIK 
which activate both pathways. However, it has yet to be determined if the 
interactions with the transcription factors are direct or possibly bridged by IKKα. 
DDX3 could act in a similar manner to what we have shown for IRF3 activation 
bringing together kinases and their substrates (Gu et al. 2013). It is also possible that 
DDX3 may additionally function in the nucleus via its interaction with the 
transcription factors p52, p65, and IRF7 as it has been suggested to act directly on 
the IFNβ promoter where it could allow formation of complexes at the promoter 
region (Soulat et al. 2008). 
A role for DDX3 acting as a scaffold protein has also been shown in a similar 
manner in work done by Cruciat et al. 2013. These authors showed that DDX3 can 
interact with an unrelated kinase to the IKKs, Casein Kinase 1 (CK1), which is 
involved in regulation of the Wnt pathway. DDX3 enhanced the activity of this 
kinase in a strikingly similar manner to what we have shown here for IKKα and 
previously shown for IKKε. DDX3 appeared to bridge the interaction between CK1 
and its substrate, dishevelled, thereby facilitating its phosphorylation. However, in 
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the case of CK1 activation it was the C-terminus of DDX3 that was required for this, 
in contrast to the N-terminus for IKKα/ε-mediated pathways.  
While the data demonstrating that DDX3 acts as a scaffold protein is quite clear, 
what has yet to be explained is the inducible nature of DDX3’s enhancement of 
signalling pathways. We have shown that the interaction between IKKα and DDX3 
is inducible upon CLO75 stimulation, but we do not yet know the link between 
stimulation of the TLR7 receptor and the induced interaction.  
Another clue may come from our observation that DDX3 may form a tetramer upon 
stimulation. We do not know what might induce the formation of these higher order 
structures, but a possible theory may come from the two studies that suggest DDX3 
acts as a PRR (Oshiumi, et al. 2010; Li et al. 2013). A common feature among PRRs 
is that upon recognition of their cognate ligand, oligomerisation takes place. A 
similar event may occur here also for DDX3. Upon binding of RNA a 
conformational change might arise in DDX3, (RNA binding by RNA helicases 
typically results in a change from an open to a closed conformation) resulting in 
formation of tetramers allowing a greater number of interactors to bind and thereby 
enhancing signalling. The fact that we did not introduce any exogenous viral RNA in 
our experimental set-ups may discount this theory. However, we cannot fully 
exclude the possibility that DDX3 could also recognise the TLR7/8 base analogue 
ligand, CLO75 which could induce a conformational change in DDX3. 
Over-expression of DDX3 could also artificially induce formation of the tetramers, 
we have seen that recombinant DDX3 BN-PAGE experiments showed band sizes 
consistent with DDX3 tetramers. The phosphorylation of DDX3 could also 
theoretically induce oligomerisation. There is also a slight possibility that, with 
DDX3 interacting with the known PRRS like TLR7, which themselves can dimerise, 
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could bring DDX3 dimers together. DDX3 has previously been shown to interact 
with the RIG-I adaptor IPS1, and the fact that RIG-I also forms dimers upon 
recognition of its ligand (Cui et al. 2008) lends itself to the possibility that two 
dimers of DDX3 may be brought into close proximity to each other via interactions 
with other mediators and structural changes could be induced to allow the formation 
of a tetramer.  
Undeniably there are a number of possibilities that have yet to be tested. DDX3 may 
indeed be a bone fide PRR and may recognise similar ligands to TLR7 and RIG-I. 
DDX3 could play a more passive role, and simply play a scaffolding role 
downstream of PRRs. In any case it is still unclear as to how DDX3 is activated to 
exert its effects on IKKα (or indeed IKKε). However,  have clearly shown here that 
it can enhance IKKα activity and that this results in increased induction of the 
pathways that are mediated by IKKα.  
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4.4 The  effect  of  IKKα  on  DDX3  
The interaction between IKKα and DDX3 is not one-sided as we have also shown 
that DDX3 is affected by this interaction by being phosphorylated by IKKα. In our 
IKKε studies we had previously shown that DDX3 was phosphorylated by IKKε on 
a number of different serines. Following on from the observation that IKKα induces 
a shift when co-expressed with IKKα, we compared the phosphorylation of DDX3 
by IKKα and IKKε. When one of these two kinases and DDX3 were co-expressed 
they each resulted in a different shift pattern in DDX3 blots. As IKKα and IKKε 
seemed to bind DDX3 on different sites, it suggested that they may also 
phosphorylate different residues, and indeed this was the case. When we tested IKKα 
phosphorylation of DDX3 with serine to alanine mutations that were found to be 
phosphorylated by IKKε in a phospho-proteomics screen, several differences were 
found in DDX3 phosphorylation. This work showed that both IKKα and IKKε share 
some phosphorylation sites in DDX3, however mutation of these residues did not 
lead to differences in IFN induction in pathways regulated by IKKα. In reporter 
assays no significant difference was found in either CLO75 of NIK/IKKα induced 
IFNβ or IFNα4 induction. It is possible that these residues play minor role in these 
pathways and effects were undetectable using this system. In any case it is apparent 
that phosphorylation of these residues by IKKα does not have an essential role in 
these pathways. It was also interesting to note that there was no significant difference 
in DDX3 phosphorylation by IKKα when serine 102 was mutated to alanine. We 
have shown previously that serine 102 phosphorylation by IKKε is essential for 
IFNβ promoter induction in IKKε mediated pathways (Gu et al. 2013). In this case 
S102 phosphorylation allowed DDX to interact with IRF3, acting as a scaffold to 
facilitate IRF3 activation by IKKε.  
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The serine 102 site also appears to be unique to IKKε. We therefore looked for 
possible sites that may be unique to IKKα. It has been shown previously that IKKα 
and IKKε can have overlapping and distinct phosphorylation sites on other 
substrates, for example p65 is phosphorylated on serine 536 by both IKKα and IKKε 
but on serine 468 by IKKε only (Mattioli et al. 2006). Our phosphoproteomics 
screen identified serines on DDX3 which are phosphorylated by both kinases 
(serines 71 and 152), but we also found serines 2, 23 and 86 which appear to be 
uniquely phosphorylated by IKKα. We produced serine to alanine site mutant 
constructs to investigate these phosphorylation sites. The preliminary data obtained 
from luciferase reporter gene assays with these mutants is not yet clear. While the 
triple serine to alanine mutation of serines 23, 71, and 152 appeared to reduce the 
enhancement of IFNβ and IFNα4 by DDX3 (Figure 45 Figure 46 Figure 47 Figure 
48), the addition of an additional mutation of S2A provided results that were harder 
to explain. The triple mutant of DDX3 points to a possible mechanism that may be 
similar to what we have shown with IKKε/IRF3 (Gu et al. 2013), that 
phosphorylation on these sites by IKKα may allow other interactions to occur. We 
cannot yet however explain the outcome with the quadruple DDX3 mutant, the 
addition of this mutation appeared to enhance the induction compared to wt DDX3. 
This could be explained by Ser2 being a site for an inhibitory/regulatory 
phosphorylation, except for the fact that the S2A mutant alone does not appear to 
alter the enhancement of IFN induction and the fact that the quadruple mutant has 
the opposite effect in the case of IFNβ induction induced by NIK/IKKα (Figure 45). 
We cannot yet say anything conclusive as further work needs to be done to 
characterise these mutants. However the apparent opposing effects of the triple and 
quadruple serine to alanine mutants of DDX3 may prove to be quite interesting. 
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Further work must be carried out to confirm these preliminary results, and to test if 
these serine mutants have altered binding affinity for some of the interactors we have 
shown here, such as IRF7 and the NF-κB subunits, and to determine whether 
phosphorylation of DDX3 actually required for interactions. It would also be 
interesting to investigate if phosphorylation of DDX3 affects its other 
functions/activities other than its role in IFNβ and IFNα4 induction   
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4.5 Relevance  of  the  IKKα-­‐DDX3  interaction    in  disease  
This new role for DDX3 in regulating IKKα activity that has been demonstrated here 
along with its previously described role in regulating IKKε activity, demonstrates 
that DDX3 is likely a key mediator in innate immune signalling. This is significant 
in the context of understanding the interplay between pathogens and the immune 
system. Its importance is greatly increased when we look at the role that these 
signalling pathways have in a number of diseases, including, for example cancer and 
auto-immune disorders. With the involvement of DDX3 in IKKα mediated pathways 
now clear, DDX3 may likely play a role in IKKα-mediated pathways that have been 
associated with disease. 
IKKα is known to have numerous roles in several important signalling pathways, it 
is not surprising then that alterations in IKKα expression and activity have been 
detected in various diseases, including a number of cancers (Liu et al. 2012; 
Nottingham et al. 2013; Margalef et al. 2012). The exact mechanisms of IKKα 
involvement in tumorgenesis are still unclear, but it appears that the nuclear roles of 
IKKα might be significant in this respect. A truncated nuclear form of IKKα has 
been identified to be associated with colorectal cancer and has been suggested as a 
possible drug target that might leave the other functions of full length IKKα intact 
(Margalef et al. 2012). In addition, aberrant signalling of the alternative NF-κB 
pathway has also been linked with various cancer including, multiple myeloma 
(Busino et al. 2012) and pancreatic cancer (Storz 2013).  
 
Additionally, while the anti-viral TLRs play a key role in recognising foreign nucleic 
acids, it has become apparent that some are also involved in auto-immune disorders, 
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where they recognise endogenous nucleic acids. TLR7 and 9 have been heavily 
implicated as playing a part in the development of systemic lupus erythematosus 
(SLE) (Celhar et al. 2012); in addition type 1 IFN is used as a biomarker for SLE 
(Elkon & Wiedeman 2012). For example TLR9 has been shown to be activated in 
response to SLE-immune complexes, containing DNA and autoantibodies (Means et 
al. 2005). The autoantibodies bind both the SLE DNA and CD32 receptors, which 
internalises the autoantibody-DNA immune complex into lysosomes where TLR9 
can be activated by the DNA (Means et al. 2005). Similarly, TLR7/8 have been 
shown to recognise small nuclear ribonucleoprotein particles contained in 
internalised SLE immune complexes (Vollmer et al. 2005). In addition an IRF5 SNP 
has been shown to be a risk factor for SLE (Graham et al. 2006) and IRAK1 has a 
crucial role in SLE (Jacob et al. 2009), further showing that the IFN-induction 
pathway downstream of TLR7/9 plays a role in this disease. In the case of TLR7/9, it 
has been suggested that these may be useful targets in the treatment of SLE, which 
might improve the efficacy of current treatments like glucocorticoids (Guiducci et al. 
2010). The fact that DDX3 is now implicated in TLR7 signalling is particularly 
interesting. As DDX3X is located on the X-chromosome and escapes X-inactivation 
(Werler et al. 2011), women have higher levels of DDX3 protein than men 
(unpublished results, Dr. Yvette Höhn, Host-Pathogen interaction Lab). Coupled 
with the fact that autoimmune diseases, such as SLE, have a far greater prevalence in 
women than men (Eaton et al. 2007), this makes DDX3 an inviting topic of research 
in this regard. 
TLR7 has been shown to be involved in a number of diseases in addition to SLE, for 
example it has been suggested as a possible target for asthma treatment as it appears 
to aid in bronchodilation via induction of nitric oxide upon agonist binding (Drake et 
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al. 2013). It has also been shown to mediate the early response to malaria infection 
(Baccarella et al. 2013). TLR inhibitors are an area that may prove to be interesting 
for the treatment of particular diseases with a number of TLR signalling modulators 
already in clinical trials, for example the TLR2 antibody OPN-305 is showing some 
promise in reducing tissue injury following ischemia/reperfusion (Arslan et al. 
2012). TLR7 and 9 agonists and antagonists are being developed for a range of 
treatments (Kandimalla et al. 2013) including cancer (Holldack 2013), sepsis (Boyd 
2012), psoriasis (Jiang et al. 2013). DDX3 could also be a potential drug target in the 
treatment of these diseases due to its role in TLR signalling and modulation of its 
function could possibly be used in a number of disease cases. 
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4.6 Conclusion  
In this work we have demonstrated a role for the DEAD-box helicase DDX3 in the 
activation of the kinase IKKα and subsequently two pathways in which IKKα is a 
key mediator – the alternative NF-κB and the TLR7 pathway to type 1 IFN 
induction. We have proposed that DDX3 acts as a scaffolding protein to bring IKKα 
in close proximity to other signalling proteins. It is likely that DDX3 binds both 
IKKα and NIK which may allow NIK to more easily activate IKKα in some 
contexts. We have also shown that DDX3 can directly enhance auto-activation of 
IKKα, possibly by bringing two IKKα proteins together allowing them to 
phosphorylate each other. The fact that we have shown that DDX3 can interact with 
so many important mediators in these signalling pathways, including transcription 
factors, lends itself to the hypothesis that it functions as a scaffold to bring substrates 
in close proximity to IKKα. Further work must be done to determine if the DDX3 
interactions with these IKKα-substrates are direct, if DDX3 function with 
transcription factors in the nucleus, and if phosphorylation of DDX3 is required for 
some interactions. With DDX3 being involved in a number of important signalling 
pathways and a possible link to diseases such as auto-immune disorders, DDX3 may 
yet prove to be an interesting drug target in the future. 
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6.2 DDX3  siRNA  sequence  
siRNA Sequence Identifier 
DDX3-­‐2 5'-­‐UUCAACAAGAAGAUCCAACAAAUCC-­‐3' (HSS102713) 
Table 6: siRNA sequence and Identifier (Invitrogen) 
 
